预约演示
更新于：2025-11-27
Moxifloxacin Hydrochloride
盐酸莫西沙星
更新于：2025-11-27
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C21H25ClFN3O4 |
InChIKeyIDIIJJHBXUESQI-DFIJPDEKSA-N |
CAS号186826-86-8 |
关联
449
项与 盐酸莫西沙星 相关的临床试验NCT03244072
Safety and Efficacy of Intracameral Zimoxin (0.1% Moxifloxacin Solution) for Prevention of Endophthalmitis After Cataract Surgery
Intracameral injection of 0.1% moxifloxacin solution after cataract surgery to prevent endophthalmitis
开始日期2026-06-01 |
申办/合作机构 |
NCT07229157
A Phase 1, Randomized, Double-blind, Placebo- and Positive-controlled, Parallel Group Study With Nested Crossover Comparison to Assess the Effect of Maridebart Cafraglutide on QT/QTc Intervals in Participants Living With Overweight or Obesity
The main objective of this trial is to evaluate the effect of maridebart cafraglutide subcutaneously (SC) on the placebo-corrected, change from baseline in QT interval corrected for heart rate using Fridericia's formula in participants living with overweight or obesity.
开始日期2025-11-18 |
申办/合作机构 |
NCT06441006
Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis (PRISM-TB)
PRISM-TB is an international, seamless, multicenter, open-label, randomized, controlled, pragmatic, stratified medicine, treatment shortening, multi-arm multi-stage (MAMS), noninferiority Phase 2/3 clinical trial for fluoroquinolone-susceptible multidrug-resistant/rifampin-resistant pulmonary tuberculosis (FQ-S MDR/RR-TB). In Stage 1, participants will be randomized among one of three treatment arms (one control and two experimental). Following the interim analysis (at the end of Stage 1) based on DOOR outcome comparisons and the entirety of the data, one of the four possible experimental strategies will be identified and continue into Stage 2. In Stage 2, participants will be randomized among one of two treatment arms (one control and one experimental).
The trial objective is to identify, among participants with fluoroquinolone-susceptible multidrug-resistant/rifampicin-resistant tuberculosis (FQ-S MDR/RR-TB), the preferred BPaLM strategy of 13 or 17 weeks for participants stratified to receive shorter treatment and 17 or 24 weeks for participants stratified to receive longer treatment, as defined by a prespecified stratification algorithm, and to evaluate whether this BPaLM strategy has noninferior efficacy to the control strategy at Week 73.
The trial objective is to identify, among participants with fluoroquinolone-susceptible multidrug-resistant/rifampicin-resistant tuberculosis (FQ-S MDR/RR-TB), the preferred BPaLM strategy of 13 or 17 weeks for participants stratified to receive shorter treatment and 17 or 24 weeks for participants stratified to receive longer treatment, as defined by a prespecified stratification algorithm, and to evaluate whether this BPaLM strategy has noninferior efficacy to the control strategy at Week 73.
开始日期2025-11-01 |
申办/合作机构 |
100 项与 盐酸莫西沙星 相关的临床结果
登录后查看更多信息
100 项与 盐酸莫西沙星 相关的转化医学
登录后查看更多信息
100 项与 盐酸莫西沙星 相关的专利（医药）
登录后查看更多信息
9,676
项与 盐酸莫西沙星 相关的文献（医药）2026-02-01·BIOSENSORS & BIOELECTRONICS
Dual-mode Tb-cyclophosphazene-MOF sensors for on-site discrimination and quantification of structurally similar flunoquinolone antibiotics in aquatic organisms via smartphone platform
Article
作者: Xing, Yong Heng ; Bai, Feng Ying ; Lv, Qiu ; Xiao, Yao ; Zhang, Ting ; Guan, Qing Lin ; Zhao, Li Na ; Zhou, Xin
We have successfully synthesized two novel terbium-cyclophosphazene MOFs (Tb-Cpz-MOFs) featuring dual-response functionality for the first simultaneous discrimination and quantification of structurally similar third- and fourth-generation fluoroquinolone antibiotics (norfloxacin, Nor: ratiometric response; moxifloxacin, Moxi: quenching response). The two Tb-Cpz-MOFs were constructed from structurally distinct cyclophosphazene-based ligands to form a two-dimensional supramolecular network and a three-dimensional framework structure, respectively. Remarkably, the Tb-Cpz-MOFs demonstrate exceptional analytical performance, achieving detection limits of 34 nM (Nor) and 9 nM (Moxi) in spiked shrimp samples, with excellent recovery rates (96.2-105 % for Nor; 95.2-107 % for Moxi). Detailed mechanistic studies combining fluorescence spectra, UV-vis absorption, theory calculations by Vienna ab initio simulation package (VASP), and XPS analysis revealed that the ratiometric response to Nor arose from its ability to capture ligand-to-Tb3+ energy transfer, while Moxi induced fluorescence quenching through competitive light absorption with MOFs. Notably, we engineered Tb-Cpz-MOFs into field-deployable PVA films integrated with smartphone colorimetry to achieve rapid visualization of dual functional detection capabilities and on-site semi quantitative analysis. This work not only provides a reliable solution for monitoring antibiotic contamination in aquatic organisms but also establishes a general design strategy for developing advanced sensors targeting structurally similar analytes.
2025-12-31·Gut Microbes
A modelling framework to characterize the impact of antibiotics on the gut microbiota diversity
Article
作者: de Gunzburg, Jean ; Burdet, Charles ; Corbel, Tanguy ; Ferreira, Stéphanie ; Olivares, Carlos ; Guedj, Jeremie ; Ruppé, Etienne ; Andremont, Antoine
Metagenomic sequencing deepened our knowledge about the role of the intestinal microbiota in human health, and several studies with various methodologies explored its dynamics during antibiotic treatments. We compared the impact of four widely used antibiotics on the gut bacterial diversity. We used plasma and fecal samples collected during and after treatment from healthy volunteers assigned to a 5-day treatment either by ceftriaxone (1 g every 24 h through IV route), ceftazidime/avibactam (2 g/500 mg every 8 h through IV route), piperacillin/tazobactam (1 g/500 mg every 8 h through IV route) or moxifloxacin (400 mg every 24 h through oral route). Antibiotic concentrations were measured in plasma and feces, and bacterial diversity was assessed by the Shannon index from 16S rRNA gene profiling. The relationship between the evolutions of antibiotic fecal exposure and bacterial diversity was modeled using non-linear mixed effects models. We compared the impact of antibiotics on gut microbiota diversity by simulation, using various reconstructed pharmacodynamic indices. Piperacillin/tazobactam was characterized by the highest impact in terms of intensity of perturbation (maximal [IQR] loss of diversity of 27.3% [1.9; 40.0]), while moxifloxacin had the longest duration of perturbation, with a time to return to 95% of baseline value after the last administration of 13.2 d [8.3; 19.1]. Overall, moxifloxacin exhibited the highest global impact, followed by piperacillin/tazobactam, ceftazidime/avibactam and ceftriaxone. Their AUC between day 0 and day 42 of the change of diversity indices from day 0 were, respectively, -13.2 Shannon unit.day [-20.4; -7.9], -10.9 Shannon unit.day [-20.4; -0.6] and -10.1 Shannon unit.day [-18.3; -4.6]. We conclude that antibiotics alter the intestinal diversity to varying degrees, both within and between antibiotics families. Such studies are needed to help antibiotic stewardship in using the antibiotics with the lowest impact on the intestinal microbiota.
2025-12-01·Current HIV/AIDS Reports
An Update on the Clinical Management of HIV and Tuberculosis Co-Infection in Pregnancy: TB Preventative Therapy, Long-Acting ARVs, and Bedaquiline-Based Regimens
Review
作者: Crocker-Buque, Tim ; Moso, Michael A ; Denholm, Justin T ; Singh, Kasha P
Abstract:
Purpose:
This update addresses HIV/TB co-infection management in pregnancy, focusing on new treatment options.
Recent Findings:
Pregnancy with HIV increases TB risk and worsens treatment outcomes. While long-acting antiretroviral therapies (LA-ART) like cabotegravir/rilpivirine and lenacapavir exist, data on their safety and efficacy in pregnant individuals are limited. Treating both HIV and TB is crucial, but pregnancy’s physiological changes complicate drug management. Standard ART and TB preventive therapy (TPT) with isoniazid are recommended after excluding active TB, despite some concerns about adverse outcomes when combined with ARV treatment. For active drug-resistant TB, the new 6-month BPaLM regimen (bedaquiline, pretomanid, linezolid, moxifloxacin) is not recommended in pregnancy due to limited safety data on pretomanid. Instead, a 9-month regimen is preferred, though bedaquiline and pretomanid are likely safe. More research on these new therapies in pregnant populations is needed.
Summary:
While standard ART remains the recommended approach for HIV/TB co-infection in pregnancy, further research is crucial to establish the safety and efficacy of newer LA-ART and bedaquiline-based TB regimens in this high-risk population. Concerns around the safety of TPT in pregnancy remain unanswered and further prospective research is urgently needed.
358
项与 盐酸莫西沙星 相关的新闻（医药）2025-11-19
·e百苑
作者
周霜 左明晏 蔡星 王海龙
作者单位
湖北中医药大学附属襄阳市中医医院肺病/呼吸与危重症医学科，襄阳 441000
通信作者
左明晏，Email：394701389@qq.com
DOI
10.3760/cma.j.cmcr20250610-02340
引用格式
周霜，左明晏，蔡星，等.免疫检查点抑制剂相关肺炎1例[DB/OL].中国临床案例成果数据库，2025（2025-09-08）.
http://journal.yiigle.com/LinkIn.do?linkin_type=cma&DOI=10.3760/cma.j.cmcr20250610-02340.
摘 要
病史摘要 患者，男性，36岁，因“间断咳嗽、呼吸困难20余天”入院。患者于2年前确诊“右舌鳞状细胞癌”，接受TP方案化疗+帕博利珠单抗治疗3个周期，治疗结束4个月后出现咳嗽，呼吸困难，CT提示双肺多发高密度影，伴间质性改变，经验性抗感染治疗无效，考虑可能是帕博利珠单抗导致的免疫相关性肺炎，予以糖皮质激素及冬虫夏草制剂治疗后，症状明显改善，复查CT病灶较前明显吸收，患者好转出院。
症状体征 体温36.2℃，脉搏112次/min，呼吸21次/min，血压121/77mmHg（1mmHg=0.133kPa），SpO294%（未吸氧）。神志清楚，精神一般，口唇轻度紫绀，双肺呼吸音低，双下肺可闻及细小湿啰音，心率112次/min，律齐，各瓣膜听诊区未闻及杂音，腹软，肝脾肋下未触及，双下肢无水肿。
诊断方法 根据患者病史、症状、体征及相关辅助检查诊断为：（1）免疫检查点抑制剂相关肺炎（3级）；（2）Ⅰ型呼吸衰竭；（3）肺炎支原体肺炎；（4）乙型流行性感冒；（5）右舌鳞状细胞癌综合治疗后；（6）慢性肾功能不全。
治疗方法 入院后给予经鼻高流量湿化治疗，激素、抗感染、雾化吸入治疗。
临床转归 患者病情好转出院，出院后嘱患者继续口服激素、冬虫夏草制剂维持性治疗。1个月后患者复查肺部CT病灶大部分吸收。
推荐阅读人群 呼吸与危重症医学科；肿瘤科
关键词 免疫检查点抑制剂；肺炎；糖皮质激素
近年来免疫治疗已成为肿瘤治疗的新热点，临床研究表明，新型的抗肿瘤免疫检查点抑制剂（immune checkpoint inhibitor，ICI）能改善晚期肿瘤患者的预后，延长肿瘤患者总生存时间[1]。临床中应用最为广泛的ICI是PD-1/PD-L1抑制剂，且在实验研究及临床肿瘤治疗中均取得了突破性进展。尽管目前PD-1/PD-L1抑制剂的使用为大量肿瘤患者带来了生存获益，但是其相关不良反应也使得患者面临了诸多困难与挑战。本文对1例使用PD-1抑制剂帕博利珠单抗后出现ICI相关性肺炎（ICI-related pneumonitis，ICIP）的舌癌患者的临床资料进行分析，旨在为临床上安全实施肿瘤免疫治疗提供一定参考。
临床资料
一、一般资料
患者，男性，36岁，因“间断咳嗽、呼吸困难20余天”入院。
现病史：患者诉20余天前无明显诱因出现咳嗽，咳少量白痰，伴活动后胸闷气喘，于当地医院查胸部CT示双肺内感染性病变，结核待排（图1A~C）；经当地医院抗感染治疗7d后症状未见明显缓解，复查胸部CT示双肺内弥漫性高密度影，感染可能性大，与上片相比，范围稍增大（图1D~F）。且患者自觉咳嗽、呼吸困难症状逐渐加重，遂来本院就诊，门诊以“呼吸困难原因待查”收入院。入院症见：咳嗽咳痰，痰色白质黏不易咳出，伴胸闷、呼吸困难，活动后加重，伴乏力，无盗汗，无恶寒发热，无胸痛咳血，无心慌，无双下肢水肿，纳一般，寐可，二便调。
既往史：2年前患者因右侧舌体包块行口腔活检，病理诊断为“右舌鳞状细胞癌”，未予特殊治疗，去年开始接受TP方案（紫杉醇+顺铂）+帕博利珠单抗（200mgiv）治疗3个周期，期间2次行胸片未见异常。患者个人史、家族遗传史、婚育史等无殊。
体格检查：体温36.2℃，脉搏112次/min，呼吸21次/min，血压121/77mmHg（1mmHg=0.133kPa），SPO294%（未吸氧），体重70kg；神志清楚，精神一般，口唇轻度紫绀，双肺呼吸音低，双下肺可闻及细小湿啰音，心率112次/min，律齐，各瓣膜听诊区未闻及杂音。腹软，肝脾肋下未触及，双下肢无水肿。
二、检查
1.一般检查。血气：血液pH值7.45，氧分压58.0mmHg↓，二氧化碳分压35.0mmHg，血氧饱和度91.0%↓。肾功能：肌酐99.2μmol/L↑，尿酸467.1μmol/L↑。肝功能、电解质、免疫球蛋白E、尿常规、粪常规均正常。
2.炎症指标。血常规：白细胞计数7.92×109/L，红细胞计数5.34×1012/L，血红蛋白148g/L；C反应蛋白26.2mg/L；红细胞沉降率测定54mm/1h；降钙素原正常。
3.特殊病原体。呼吸道病原体检测：抗乙型流感病毒抗体IgM弱阳性反应，肺炎支原体IgM（荧光）阳性反应。新型冠状病毒核酸、咽拭子、痰培养及鉴定、抗人免疫缺陷病毒抗体（定量）、血液G试验+GM试验、肺泡灌洗液GM实验：均未见明显异常；外送肺泡灌洗液tNGS：致病性病原菌未检出；肺泡灌洗液结核菌涂片、tbDNA、细胞学检查均未见明显异常。
4.风湿免疫。风湿病检测：抗核提取物抗体nRNP/SM弱阳性反应。抗链球菌溶血素O、类风湿因子、ANCA相关性血管炎检测、抗环瓜氨酸抗体、角蛋白抗体均正常；
5.肿瘤标记物。肿瘤标记物（呼吸）：神经元特异性烯醇化酶24.40ng/ml↑，细胞角蛋白19片段20.8ng/ml↑。
6.心脏。心电图：心率107次/min，诊断窦性心动过速。心脏彩超：EF60%，心率增快。心肌酶、心损、BNP均正常。
7.肺功能：FVC50.8%↓，FEV150.3%↓，FEV1/FVC82.65，DLCOSB34.7%↓。中重度限制性通气功能障碍；肺弥散功能重度下降。
8.胸部CT（当地医院治疗前，图1A~C）：双肺内感染性病变，结核待排。胸部CT
（当地医院治疗7d后，图1D~F）：双肺内弥漫性高密度影，感染可能性大，其他待排，与上片相比，范围稍增大。胸部CT（本院治疗5d后，图1G~I）：双肺感染性病变，机遇性感染？纵隔淋巴结增大。
图1 患者胸部CTA~C：当地医院治疗前胸部CT；D~F：当地医院治疗7d后胸部CT；G~I：本院治疗5d后胸部CT
三、诊断与鉴别诊断
诊断：（1）免疫检查点抑制剂相关肺炎（3级）；（2）Ⅰ型呼吸衰竭；（3）支原体肺炎；（4）乙型流行性感冒；（5）右舌鳞状细胞癌综合治疗后；（6）慢性肾功能不全。诊断依据：患者，男性，36岁，以咳嗽、呼吸困难为主症，起病急，病程短。患者入院前肺部CT提示双肺多发弥漫性高密度影，经验性抗感染治疗7天后咳嗽、呼吸困难症状无明显改善，复查胸部CT提示病灶较前进展。遂转至本院住院，入院后呼吸道病原学提示是肺炎支原体抗体IgM及乙型流感病毒抗体IgM阳性，诊断为肺炎支原体肺炎及乙型流感，予以对症抗感染、抗病毒治疗。治疗5d后复查肺部CT见双肺多发弥漫性高密度斑片影，伴双肺间质性改变，对比入院前CT病灶再次进展（见图1G~I）。2次抗感染治疗失败考虑非感染性疾病或特殊病原体感染可能。同时支气管镜BALF送检tNGS及其他辅助检查结果回报可排除细菌、病毒、支原体、肺孢子菌、曲霉菌、结核、风湿免疫性疾病、肺水肿、肺栓塞等。结合患者既往舌鳞状细胞癌病史，行帕博利珠单抗治疗后4个月出现咳嗽，呼吸困难症状，血氧饱和度下降，双下肺听诊可闻及爆裂音，肺部CT为近期新发病灶且短期内变化较快，符合免疫检查点抑制剂相关肺炎（CIP）诊断标准，参考2021年《中国临床肿瘤学会（CSCO）免疫检查点抑制剂相关毒性管理指南》[2]，根据患者肺部表现及体征判断，本例患者可诊断为CIP3级。
鉴别诊断：（1）肺血栓栓塞症。患者青年男性，既往舌鳞状细胞癌病史，属血栓高危人群，此次急性起病，持续低氧血症，双肺多发实变影，注意与肺栓塞鉴别。肺栓塞症状不特异，可有呼吸困难、胸痛、咯血、晕厥，持续性低氧血症、低血压等情况；部分肺栓塞病例CT可出现胸膜下实变影（肺梗死）；可通过D-二聚体、胸部CT、下肢血管超声、超声心动图等进行筛查，必要时可行CT肺动脉造影明确诊断。（2）肺炎。患者化疗+免疫治疗后，免疫严重受损，易发生肺部感染，须注意与大叶性肺炎鉴别。大叶性肺炎以急性高热、寒战、脓痰、胸膜炎性胸痛为主要表现，病情进展较快；CT表现为均一的大叶性实变，边界清晰，常见空气支气管征，实变区密度较高；可完善痰液或支气管肺泡灌洗液培养、NGS检测、血清β-D-葡聚糖检测、呼吸道样本核酸/抗原检测、血清特异性抗体或核酸测定寻找病原学依据。（3）肿瘤进展。患者双肺多发实变影伴小叶间隔增厚，不排除舌癌转移至肺部所致，应注意与转移性肿瘤鉴别。转移性癌性淋巴管炎可以出现肺间质改变；CT表现为小叶间隔增厚，多为串珠样不规则增厚；可完善支气管镜、BALF细胞学进行排查，必要时行肺活检。
四、治疗
入院后给予常规护理、优质蛋白饮食、经鼻高流量氧疗（流量40~50L/min，氧浓度50%）、监测血氧饱和度、抗感染（莫西沙星400mgivdropqd）、雾化吸入（复方异丙托溴铵溶液2.5ml+布地奈德混悬剂2mg、雾化、bid）等治疗方案。经过5d的治疗后，患者诉咳嗽、咳痰、呼吸困难等症状无明显缓解，复查胸部CT病灶较前再次进展，结合患者肿瘤史，免疫检查抑制剂使用史及其他相关检查，考虑免疫检查抑制剂相关肺炎3级，调整治疗方案为甲泼尼龙40mgivdropbid，复方异丙托溴铵溶液2.5ml+布地奈德混悬剂2mg、雾化、bid，冬虫夏草制剂4粒potid，兰索拉唑肠溶片30mgpoqd，停用莫西沙星，停免疫抑制剂治疗。激素治疗2d后患者咳嗽、呼吸困难症状明显改善，激素治疗8d后甲泼尼龙减量至40mgivdropqd，余治疗不变。激素治疗12d后患者无明显咳嗽，活动后稍有气喘，复查胸部CT提示双肺病灶较前明显吸收（图2）。
图2 激素治疗12d后胸部CT
五、治疗结果、随访及转归
患者病情稳定，复查胸部CT提示病灶较前明显吸收，达到出院标准。出院后治疗方案为甲泼尼龙32mgpoqd（每周减1片），冬虫夏草制剂4粒potid，兰索拉唑肠溶片30mgpoqd，长期家庭氧疗，肺康复锻炼。出院后1个月复查胸部CT病灶较前进一步吸收（图3），调整治疗方案为甲泼尼龙16mgpoqd（每周减1片），冬虫夏草制剂4粒potid，兰索拉唑肠溶片30mgpoqd。嘱患者出院后2个月后继续来院复查胸部CT。
图3 出院后1个月胸部CT
讨 论
帕博利珠单抗（Pembrolizumab）是一种可与程序性死亡蛋白-1（PD-1）受体结合的人源化单克隆抗体，可阻断PD-1受体与其配体PD-L1和PD-L2结合，从而解除对T细胞增殖和细胞因子生成的抑制作用，恢复T细胞抗肿瘤活性，从而增强免疫应答。该药于2018-07在我国上市，CFDA批准用于经一线治疗失败的不可切除或转移性黑色素瘤、PD-L1肿瘤比例分数（TPS）≥1%的表皮生长因子受体（epidermal growth factor receptor，EGFR）基因突变阴性和间变性淋巴瘤激酶（anaplastic lymphoma kinase，ALK）阴性的局部晚期或转移性非小细胞肺癌一线单药治疗、联合培美曲塞和铂类化疗适用于EGFR阴性和ALK阴性的转移性非鳞状非小细胞肺癌一线治疗、联合卡铂和紫杉醇用于转移性鳞状非小细胞肺癌一线治疗及食管癌。值得注意的是PD-1抑制剂使恶性肿瘤患者广泛受益的同时，还会非特异性激活免疫系统引起离散毒性，由此引起相应器官出现炎症症状，即免疫相关性不良反应（immune-related adverse events，irAEs）[3]。免疫相关性肺炎（immune-checkpo intinhibitor-related pneumonitis，CIP）是一种常见的irAEs，发病率3%~5%[4]。文献报道[5]PD-1抑制剂单药治疗时CIP发生率为2.7%，重症（≥3级）发生率为0.8%，而联合治疗CIP发生率6.6%，显著高于单药治疗。
CIP多出现在首次使用以帕博利珠单抗为代表的ICI后的0.5~24.3个月，中位发病时间为2.6个月[6]。Naidoo等[7]报道了43例经PD-1/PD-L1抑制剂治疗的患者发生CIP的中位时间为2.8个月，联合细胞毒性T淋巴细胞相关抗原4抑制剂时发生CIP的中位时间为2.7个月，较单药治疗出现更早。本例的CIP发病时间为用药后4个月，稍晚于文献报道的中位发病时间，考虑患者可能前期有影像学改变而无症状，因此发现时间较晚。免疫相关性肺炎在帕博利珠单抗注射液说明书及相关文献中有描述，属于已知的不良反应类型；本例患者在帕博利珠单抗停药后4个月影像学检查提示双肺弥漫性高密度影伴间质性改变，经糖皮质激素治疗后明显缓解；给予帕博利珠单抗治疗期间并未使用其他免疫调节药，且患者的症状表现为irAEs。根据国家药品不良反应监测中心《药品不良反应术语使用指南》[8]中关联性评价标准，可判断本例不良反应的关联性评价为“很可能”。
CIP无特征性临床表现，常以咳嗽、呼吸困难等症状为主，部分患者可伴有发热、胸痛[9]。然而，最容易被忽视的是约33%患者仅出现影像学异常，无任何临床表现[10]。据统计接受PD-1/PD-L1抑制剂治疗的患者，20%~40%的患者伴咳嗽、呼吸困难等症状，其中3~4级咳嗽占2%~9%，3~4级呼吸困难占1%~2%[10-11]。CIP是药物相关性间质性肺炎，与其他间质性肺疾病（ILD）类似，胸部高分辨率CT（HRCT）能更好地评价CIP的形态学特征。其影像学表现多种多样[12]，主要包括机化性肺炎样改变、非特异性间质性肺炎样改变、过敏性肺炎样改变、弥漫性肺泡损伤（急性间质性肺炎或急性呼吸窘迫综合征）样改变和普通型间质性肺炎样改变等[13-14]。此外，肺炎的影像学类型可能与临床严重程度和分级相关，如弥漫性肺泡损伤（急性间质性肺炎或急性呼吸窘迫综合征）样改变提示较高级别的肺炎以及较差的临床预后，其次是机化性肺炎样改变，而非特异性间质性肺炎样改变和过敏性肺炎样改变与较低级别的肺炎相关[15-17]。症状和CT的非特异性决定了CIP的诊断是排他性诊断，本例患者以咳嗽，呼吸困难为主要临床表现，肺部CT以非特异性间质性肺炎样改变为主，在排除感染性肺炎、肺水肿、肺泡出血、风湿免疫性疾病、肿瘤进展等疾病后，最终考虑患者所表现出的症状为CIP。且本例患者情进展较弥漫性肺泡损伤相对较慢，经规范化治疗后预后尚可。
CIP的药物治疗，主要是根据病情的严重程度分级、进展速度、患者的基础疾病状况制定，包括糖皮质激素、免疫抑制剂、免疫球蛋白、生物制剂等治疗。激素是CIP的一线治疗药物，关于激素用量尚无统一定论，美国肿瘤学会指南和欧洲肿瘤内科学会指南推荐对于3~4级CIP，起始治疗静脉给予大剂量激素，不低于1mg/（kg·d）泼尼松当量，疗程6~8周以上。但若2级CIP患者，在监测过程中出现疾病进展、呼吸困难等临床表现，可以口服糖皮质激素，一般起始剂量在0.5~1mg/（kg·d），总疗程建议4~6周。激素依赖性、复发性CIP患者，若无禁忌，建议尽早联合免疫抑制剂。对于重症和危重症CIP患者，可考虑在初始激素治疗时，联合抗IL-6制剂、抗TNF-α制剂等生物制剂和（或）JAK抑制剂，以及联合丙种球蛋白治疗。本例患者诊断为CIP3级，予以甲泼尼龙总量80mg/d，同时建议患者永久停用帕博利珠单抗，经治疗48h后症状明显改善，遂根据欧洲肿瘤内科学会指南暂不予以免疫抑制剂治疗。
CIP属于药物性间质性肺病，在中医辨证中CIP属肺痿范畴，除西药外，中药在治疗间质性肺病方面有着独特优势。庞立健等认为肺痿的病机当于本虚标实中求之，肺肾气虚、肺肾阴虚为本虚一方，瘀血（痰、湿、毒）为标实一面，虚和邪实相互影响互为因果形成阴虚致实、因实致虚、虚者更虚、实者更实的病理特点[18]。冬虫夏草为补益药，可补肺气以助其宣降，助肾阳以渔肾纳气，滋肺肾之阴以降上炎虚火。2005年版《中国药典》记载冬虫夏草“补肺益肾，止血化痰；用于久咳虚喘，劳嗽咯血……”强调冬虫夏草在保肺益肾方面起到重要作用。
抗肿瘤免疫治疗中并发的CIP是少见的免疫相关不良反应类型，一旦发生，会严重影响后续的抗肿瘤免疫治疗，甚至导致呼吸衰竭或死亡。但若能及早被识别、诊断，并给予及时、合理的治疗，大多数患者预后良好，部分患者有可能后续接受免疫再挑战。冬虫夏草制剂辅助治疗CIP较单用糖皮质激素能有效缩短治疗时间减少使用激素的不良反应，减轻患者的痛苦，提高患者的生存质量，毒副作用小，患者易于接受。
利益冲突声明
所有作者声明不存在利益冲突
参考文献
[1]Theelen WSME, Chen D, Verma V, et al. Pembrolizumab with or without radiotherapy for metastatic non- small-cell lung cancer:a pooled analysis of two randomised trials[J]. Lancet Respir Med, 2021, 9(5): 467-475.
[2] 中国临床肿瘤学会指南工作委员会组织. 中国临床肿瘤学会（CSCO）免疫检查点抑制剂相关毒性管理指南-2021[M]. 北京：人民卫生出版社，2021.
[3] 唐淑慧，李丽，侯黎莉. PD-1抑制剂免疫相关不良反应的研究进展[J]. 临床与病理杂志，2021，41（3）：720-725.
[4] 倪军，张力. 肿瘤免疫治疗相关不良反应研究进展[J]. 中华内科杂志，2021，60（1）：84-89.
[5] Nishino M, Giobbie HA, Hatabu H, et al. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer:a systematic review and meta-analysis[J]. JAMA Oncol, 2016, 2(12): 1607-1616.
[6] Theelen WSME, Chen D, Verma V, et al. Pembrolizumab with or without radiotherapy for metastatic non- small-cell lung cancer: a pooled analysis of two randomised trials[J]. Lancet Respir Med, 2021, 9(5): 467-475.
[7] Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1 /programmed death ligand 1 therapy[J]. J Clin Oncol,2017,35( 7): 709-717.
[8] 国家药品不良反应监测中心. 药品不良反应术语使用指南[S]. 北京：国家药品不良反应监测中心，2016.
[9] 顾永丽，孙增先. 帕博利珠单抗致免疫相关性肺炎和心肌炎1例[J]. 中国新药与临床杂志，2021，40（2）：155-157.
[10] 黄贵东，廖露琴，朱玲，等. 肺癌患者使用帕博利珠单抗致免疫相关肺炎的药学监护[J]. 中南药学，2020，18（8）：1418-1421.
[11] Martin R, Delvys RA, Andrew GR, et al. Pembrolizumab versus chemotherapy for PD-L1 positive non-small- cell lung cancer[J]. N Engl J Med, 2016, 375(19): 1823-1833.
[12] 刘燕娥. 免疫检查点抑制剂相关肺炎的诊治新进展[J]. 中外医学研究，2018，16（22）：179-181. [13]Naidoo J, Wang X, Woo KM, et al. Pneumonitis in Patients Treated With Anti-Programmed eath-1/Programmed Death Ligand 1 Therapy[J]. J Clin Oncol, 2017, 35(7): 709-717.
[14] Nishino M, Ramaiya NH, Awad MM, et al. PD‑1 Inhibitor‑Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course[J].Clin Cancer Res, 2016, 22(24): 6051-6060.
[15] Cho JY, Kim J, Lee JS, et al. Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer[J]. Lung Cancer, 2018, 125: 150-156.
[16] Delaunay M, Cadranel J, Lusque A, et al. Immune‑checkpoint inhibitors associated with interstitial lung disease in cancer patients[J]. Eur Respir J, 2017, 50(2): 1700050.
[17] Johkoh T, Lee KS, Nishino M, et al. Chest CT Diagnosis and Clinical Management of Drug‑Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner Society[J]. Chest, 2021, 159(3): 1107-1125.
[18] 庞立健，王琳琳. 肺纤维化的中医病机初探[J]. 中华中医药学刊，2011，29（7）：1596-1597.
点击下方卡片进入小程序
参与讨论、与作者在线交流
欢迎广大医学生、医生朋友们
点击下方关注中华病例说公众号进入小程序
期待您的分享和互动～
e百苑
临床研究
2025-11-18
·格隆汇
解码肺结核药物：抗痨治疗的核心医疗武器肺结核药物是针对结核分枝杆菌感染开发的特异性抗菌药物体系，通过抑制细菌细胞壁合成、干扰核酸代谢或蛋白质合成等机制实现杀菌或抑菌效果，是全球结核病防控体系的核心组成部分。其核心价值不仅在于治愈个体患者，更在于阻断疾病传播、遏制耐药菌株扩散，需遵循 “早期、联合、适量、规律、全程” 的治疗原则。从公共卫生视角看，这类药物的可及性与疗效直接关系到全球终结结核病目标的实现，尤其在耐药性结核病高发地区，新型药物更成为突破治疗困境的关键。市场图景：稳健增长的抗传染病刚需赛道全球肺结核药物市场正处于需求稳定释放与创新动能培育的发展阶段。据 Global Info Research（环洋市场咨询）调研数据显示，2024 年全球该领域收入已达到约 1311 百万美元，依托结核病的高发性与防控刚需形成坚实市场基础。展望未来，市场将保持平稳扩张态势，预计到 2031 年，市场收入将攀升至 1771 百万美元，在 2025 至 2031 年期间，年复合增长率（CAGR）维持在 4.4%，虽增速不及高端创新药领域，但凭借疾病防控的刚性需求实现持续增长。产品图谱：分层治疗导向的药物分类体系根据临床治疗优先级与适用场景的差异，肺结核药物形成三类核心产品矩阵，分别对应不同感染类型与病情阶段：一线药物治疗：作为初治敏感结核病的首选方案，以异烟肼、利福平、乙胺丁醇、吡嗪酰胺为核心代表，具有杀菌作用强、价格低廉、副作用相对可控的优势。其中异烟肼易透过血 - 脑屏障，对中枢神经系统结核感染疗效显著；利福平具备广谱抗菌特性，与异烟肼联用可增强疗效并延缓耐药性产生；吡嗪酰胺则能针对性杀灭酸性环境中的结核分枝杆菌，是短程化疗方案的关键组成。这类药物构成全球结核病治疗的基础用药池，占据市场销量的主要份额。：主要用于一线药物耐药或存在严重不良反应的患者，包括阿米卡星、卷曲霉素等氨基糖苷类抗生素，以及对氨基水杨酸、乙硫异烟胺等化学合成药物。阿米卡星与卷曲霉素对耐药菌株具有较强抗菌活性，但需注意肾毒性与耳毒性等不良反应监测；对氨基水杨酸疗效虽不及一线药物，但在联合治疗中可发挥协同作用。随着耐药结核病发病率上升，二线药物市场需求呈稳步增长态势。联合药物治疗：以固定剂量复合制剂（FDCs）为主要形式，将多种一线或二线药物按优化剂量组合制成单一剂型，如异烟肼 - 利福平 - 吡嗪酰胺三联制剂、含莫西沙星的四联耐药方案等。这类产品能简化用药流程、提高患者依从性，有效降低因漏服、错服导致的耐药风险，已被世界卫生组织（WHO）推荐为优先治疗方案。部分联合制剂还纳入新型药物成分，进一步缩短治疗周期，提升重症患者治愈率。应用场景：分级诊疗体系下的精准给药场景肺结核药物的临床应用高度依托医疗服务体系的分级诊疗格局，重点覆盖三大核心场景，其配置逻辑与疾病防控策略紧密相关：医院：作为重症与复杂病例的核心治疗场景，承担初治重症、耐药结核病及合并症患者的治疗任务。医院可开展药敏试验与耐药基因检测，为患者制定个体化联合用药方案，例如对耐多药患者采用 “二线注射剂 + 新型口服药” 的长程方案，或对极耐药患者启用含 macozinone 等试验性药物的挽救治疗。同时，医院负责药物不良反应监测与处理，保障治疗安全性。私人诊所：主要服务于轻症初治患者与巩固治疗期患者，以标准化一线联合药物治疗为主。在结核病高发地区，规范的私人诊所可纳入基层防控网络，通过提供固定剂量复合制剂与服药指导，提升患者全程治疗依从性。部分私人诊所还承担随访复查与健康宣教职能，助力实现 “治疗 - 管理” 一体化。其他：涵盖社区卫生服务中心、传染病防治机构及特殊场所治疗点等场景。社区卫生服务中心负责辖区内患者的定期随访与药物发放，确保治疗连续性；传染病防治机构则聚焦疫情监测与耐药筛查，为区域用药策略制定提供数据支撑；监狱、养老院等特殊场所的治疗点则针对聚集性感染风险，实施集中给药与管理，阻断交叉传播。增长引擎：防控需求与技术突破的协同驱动全球肺结核药物市场的稳健增长得益于多重因素的共同作用，形成 “防控刚需 - 技术迭代 - 政策支撑” 的增长三角：从需求端来看，全球结核病负担依然沉重，2024 年新发患者超 1070 万，耐多药病例占比持续上升，推动二线药物与联合制剂需求刚性增长；同时，HIV 合并感染人群的治疗需求与移民群体的防控需求进一步扩大市场基数。从技术端而言，新药研发与制剂创新注入增长动能，macozinone、sutezolid 等新型药物进入临床试验阶段，有望突破耐药治疗瓶颈，固定剂量复合制剂的剂型优化则提升产品竞争力。从政策端分析，全球健康组织的防控投入持续增加，WHO “终止结核病战略” 推动药物可及性提升，部分国家将耐药结核病药物纳入医保报销，降低患者支付门槛。此外，仿制药企业的产能扩张与成本控制，使基础用药在低收入国家的可及性显著改善。市场主体：全球核心参与企业阵营全球范围内深耕肺结核药物领域的主要企业包括 Pfizer Inc、Lupin Laboratories Ltd、AstraZeneca Plc、Cadila Pharmaceuticals、Novartis AG、Alkem Laboratories Ltd、Cipla Ltd、Otsuka Pharmaceutical、Sanofi、Abbott、ANI Pharmaceuticals, Inc、Teva Pharmaceutical Industries Ltd、Macleods Pharmaceuticals Ltd.、Johnson & Johnson、FRESENIUS SE & Co. KGaA (Fresenius Kabi)、Eli Lilly and Company、Viatris Inc. (Mylan N.V.)、Sun Pharmaceutical Industries Ltd.。这些企业形成 “原研药企 + 仿制药巨头” 的竞争格局，原研企业聚焦新型药物研发，仿制药企业则主导基础用药市场，通过产能与成本优势抢占新兴市场份额。未来展望：精准化与可及性并行的发展新路径随着结核病防控策略升级与医药技术进步，全球肺结核药物市场将朝着 “精准治疗、短程高效、全民可及” 的方向演进。未来，新药研发将聚焦耐药机制突破，新型口服药物与非注射方案有望替代传统二线注射剂，将耐药结核病治疗周期从 18-24 个月缩短至 6-9 个月；联合制剂将向 “多靶点、低毒副” 升级，进一步提升患者依从性。在市场格局上，新章节内容概述第1章：研究肺结核药物定义、统计范围、产品分类、应用等介绍，全球肺结核药物总体规模及预测（2020-2031）第2章：重点分析全球肺结核药物市场的企业，包括生产商的基本情况、主营业务及主要产品类型、销量、收入、价格、最新动态等（2020-2025）第3章：深入分析全球肺结核药物的竞争态势，主要Top3和Top5企业的销量、价格、收入及份额、相关业务/产品布局以及下游应用/市场，同时也分析肺结核药物行业并购，新进入者及扩产情况（2020-2025）第4章：研究全球肺结核药物主要地区的规模，包括北美、欧洲、亚太、南美、中东及非洲市场的收入（2020-2031）第5章：肺结核药物产品类型的销量、收入、价格（2020-2031）第6章：肺结核药物应用领域的销量、收入、价格（2020-2031）第7章：北美地区肺结核药物按国家、产品类型和应用拆分，细分规模及预测（2020-2031）第8章：欧洲地区肺结核药物按国家、产品类型和应用拆分，细分规模及预测（2020-2031）第9章：亚太地区肺结核药物按地区、产品类型和应用拆分，细分规模及预测（2020-2031）第10章：南美地区肺结核药物按地区、产品类型和应用拆分，细分规模及预测（2020-2031）第11章：中东及非洲地区肺结核药物按地区、产品类型和应用拆分，细分规模及预测（2020-2031）第12章：肺结核药物市场动态，包括驱动因素、阻碍因素、影响因素第13章：肺结核药物的产业链分析第14章：肺结核药物的销售渠道分析第15章：报告结论 查看更多内容或申请样本:https://www.globalinforesearch.com.cn/reports/2441284/tuberculosis-drugs 报告作用：了解肺结核药物市场规模和发展动向掌握政策：政策引领肺结核药物行业发展，阻力企业市场布局规避风险：肺结核药物竞争对手SWOT分析，投资成本，利润分析，洞察未来发展趋势洞悉行情：肺结核药物历史数据+预测数据涵盖11年数据，全方位布局掌握市场动态走势提升效益：分析肺结核药物上下游的市场机会帮助企业寻求效益突破口 出版商：广州环洋市场信息咨询有限公司微信/电话： 176 6505 2062邮箱：report@globalinforesearch.com中文官网：https://www.globalinforesearch.com.cn英文官网：https://www.globalinforesearch.com
2025-11-17
Journal of Antimicrobial Chemotherapy Volume 80, Issue 7抗菌化疗杂志 80卷 7期
https://academic.oup.com/jac/issue
REVIEWS（综述）
1
The role of antimicrobial prophylaxis in brachytherapy for prostate, breast and gynaecological cancer: a narrative review
抗生素预防用药在前列腺、乳腺及妇科癌症近距离治疗中的作用：叙述性综述
Konstantinos Alexakis and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1753–1771,
2
To be or not to be: the non-antimicrobial properties of common antimicrobials
生存还是毁灭：常见抗菌药物的非抗菌特性
Shivakumar Narayanan and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1772–1783,
SYSTEMATIC REVIEWS（系统综述）
3
Antibiotic-induced Bartter-like syndrome: a systematic review
抗生素诱发的巴特综合征样表现：系统综述
Megha Priyadarshi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1784–1791,
4
Liposomal amphotericin B prophylaxis in paediatrics: a systematic review
两性霉素B脂质体预防性用药在儿科中的应用：系统综述
Emma V Thorley and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1792–1802,
ORIGINAL RESEARCH（论著）
5
Antibiotic use attributable to RSV infections during infancy—an international prospective birth cohort study
婴儿期呼吸道合胞病毒感染所致抗生素使用情况——一项国际前瞻性出生队列研究
Sarah F Hak and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1803–1812,
6
Plasmodium falciparum isolates: ex vivo drug response
恶性疟原虫分离株：体外药物反应
Edem Adika and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1813–1822,
7
Impact of hypoalbuminemia on patients receiving ertapenem combination therapy for methicillin-susceptible Staphylococcus aureus bacteraemia
低白蛋白血症对接受厄他培南联合疗法治疗甲氧西林敏感金黄色葡萄球菌菌血症患者的影响
Sunish Shah and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1823–1827,
8
Exploring community pharmacy professionals and general practitioners’ views on primary care communication and pathways to access antibiotics in England
探究英国社区药房专业人员和全科医生对初级保健沟通及获取抗生素途径的看法
Ming Xuan Lee and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1828–1836,
9
Decline of antimicrobial resistance in Pseudomonas aeruginosa bacteraemia following the COVID-19 pandemic: a longitudinal observational study
新冠疫情后铜绿假单胞菌菌血症抗菌药物耐药性的下降：一项纵向观察研究
Yulia Butscheid and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1837–1848,
10
Selected comorbidities and the probability of ART switch in PWH with undetectable HIV-RNA: a retrospective analysis in Italy
意大利HIV感染者（HIV-RNA不可检测）特定合并症与抗逆转录病毒药物转换概率：一项回顾性分析
Alessandro Cozzi-Lepri and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1849–1859,
11
Model-based translation of the PKPD-relationship for linezolid and vancomycin on methicillin-resistant Staphylococcus aureus: from in vitro time–kill experiments to a mouse pneumonia model
基于模型转化利奈唑胺和万古霉素对甲氧西林耐药金黄色葡萄球菌的药代动力学-药效学关系：从体外时间杀菌实验到小鼠肺炎模型
Diego Vera-Yunca and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1860–1868,
12
Inner-mitochondrial membrane protein PfMPV17 is linked to P. falciparum in vitro resistance to the indoloquinolizidine alkaloid alstonine
线粒体内膜蛋白PfMPV17与恶性疟原虫对吲哚醌啉生物碱阿尔斯通宁的体外耐药性相关
J R Macdonald and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1869–1877,
13
Efficacy and tolerability of the combination of minocycline and metronidazole for macrolide-resistant Mycoplasma genitalium
米诺环素与甲硝唑联合治疗大环内酯类耐药生殖支原体感染的疗效和耐受性
Kay Htaik and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1878–1884,
14
Early use of the novel antifungal rezafungin: a case series and literature review
新型抗真菌药物瑞扎芬净的早期使用：病例系列报道及文献综述
H C Davidson and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1885–1892,
15
Optimal dosing of amoxicillin in obese and post-gastric bypass patients using a population pharmacokinetics-pharmacodynamics model approach
基于群体药代动力学-药效学模型方法确定阿莫西林在肥胖和胃旁路术后患者中的最佳剂量
Gisela Myrian de Lima Leite Dalla Rosa and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1893–1901,
16
Decreasing antimicrobial resistance in representative UK livestock species was associated with reduced total sales of antimicrobials in the last decade
过去十年，英国代表性家畜物种抗菌药物耐药性下降与抗菌药物总销量减少相关
Aliya El Nagar and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1902–1906,
17
An improved multiplex RT–quantitative PCR assay can reveal sex-specific activity of transmission-blocking drugs on ex vivo gametocytes from Plasmodium falciparum asymptomatic infections
一种改进的多重逆转录定量聚合酶链反应检测法可揭示性特异性抗疟疾传播阻断药物对恶性疟原虫无症状感染体外配子体活性的影响
Mariagrazia Ciardo and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1907–1914,
18
Population pharmacokinetics and thrombocytopenia risk assessment of linezolid in liver transplant recipients
利奈唑胺在肝移植受者中的群体药代动力学及血小板减少症风险评估
Xiaoping Shi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1915–1925,
19
Rapid susceptibility testing on urine for antimicrobial stewardship in general practice
全科实践中的尿液快速药敏试验助力抗菌药物管理
Patrick D J Sturm and Tanja Schülin
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1926–1932,
20
Efficacy of linezolid in monotherapy q12h versus q8h versus combined with daptomycin in the treatment of experimental endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus strains
利奈唑胺单药治疗每12小时一次与每8小时一次，以及与达托霉素联合治疗甲氧西林耐药和糖肽中介金黄色葡萄球菌菌株所致实验性心内膜炎的疗效
María-Alexandra Cañas and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1933–1941,
21
In vitro activity of NOSO-502, a novel-action antimicrobial, against clinical strains of Enterobacterales including MDR strains
新型作用机制抗菌药物NOSO-502对包括多重耐药菌株在内的肠杆菌科临床菌株的体外活性
Marie L G Attwood and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1942–1946,
22
Antibacterial activity of propylene glycol against Staphylococcus aureus and Staphylococcus epidermidis in neutral and mild acidic conditions
中性及弱酸性条件下，丙二醇对金黄色葡萄球菌和表皮葡萄球菌的抗菌活性
Nadiia Mosiichuk and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1947–1950,
23
Molecular characteristics of chromosome-mediated colistin resistance in foodborne Salmonella isolates in China
中国食源性沙门氏菌分离株染色体介导的多粘菌素耐药性的分子特征
Zeqiang Zhan and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1951–1963,
24
High azole non-wild type rates and nosocomial microsatellite typing aggregation of Wickerhamomyces anomalus in China according to a 12-year multicenter surveillance study
根据一项为期12年的多中心监测研究，中国异常威克汉姆酵母属唑类非野生型率高且医院内微卫星分型聚集
Zhengyu Luo and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1964–1971,
25
Repurposing antimalarials: pyrimethamine exhibits superior in vitro activity to metronidazole against Gardnerella while sparing Lactobacillus
抗疟药物再利用：乙胺嘧啶对加德纳菌的体外活性优于甲硝唑，且对乳酸杆菌无影响
Aliona S Rosca and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1972–1979,
26
Clinical characteristics and risk factors of tigecycline-induced acute pancreatitis in kidney transplant recipients: a retrospective study
肾移植受者替加环素诱发急性胰腺炎的临床特征及危险因素：一项回顾性研究
Lijuan Feng and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1980–1987,
27
Genomic characteristics of the multiresistant Acinetobacter baumannii global clone 1 reference strain A297/RUH875
多重耐药鲍曼不动杆菌全球克隆1型参考菌株A297/RUH875的基因组特征
Jonathan Koong and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1988–1992,
28
Comparison of a modified broth microdilution Sensititre™ SLOMYCOI assay with the CLSI-recommended agar disk elution method for antimicrobial susceptibility testing of Mycobacterium haemophilum
改良肉汤微量稀释Sensititre™ SLOMYCOI检测法与CLSI推荐的琼脂稀释法对嗜血杆菌属抗菌药物敏感性检测的比较
Doris Hillemann and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1993–1996,
29
Reversal of phenotypic resistance in multi-drug resistant carbapenemase-producing K. pneumoniae clinical isolates due to in vitro synergistic interactions between bacteriophages and antibiotics at clinically achievable concentrations
由于细菌噬菌体和抗生素在临床可达到浓度下的体外协同作用，多重耐药碳青霉烯酶产生肺炎克雷伯菌临床分离株的表型耐药性发生逆转
Paschalis Paranos and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1997–2006,
30
Antibiotic resistance and population structure of Staphylococcus epidermidis from prosthetic joint infections in Sweden and France
瑞典和法国假体关节感染表皮葡萄球菌的抗生素耐药性和群体结构
Sofie M Edslev and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2007–2015,
31
Lines on the line: evaluating the impact of antibiotic lock therapy versus catheter removal in the management of central vascular catheter infections
抗生素锁疗法与导管拔除术治疗中心血管导管感染的影响评估
Nischal Ranganath and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2016–2024,
32
Real-time FT-IR typing of Klebsiella pneumoniae: a flexible and rapid approach for outbreak detection and infection control
肺炎克雷伯菌实时傅里叶变换红外分型：一种灵活快速的暴发检测和感染控制方法
Ana Beatriz Gonçalves and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2025–2031,
33
Antibiotic stress affects the secretion and physicochemical features of extracellular vesicles produced by Helicobacter pylori
抗生素压力影响幽门螺杆菌产生的细胞外囊泡的分泌和物理化学特性
Paweł Krzyżek and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2032–2043,
34
A novel azithromycin resistance mutation in Mycoplasma genitalium induced in vitro
生殖支原体体外诱导产生的新型阿奇霉素耐药突变
Teck-Phui Chua and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2044–2050,
RESEARCH LETTERS（研究信函）
35
Posaconazole dosing of enteral formulations in infants and young children to achieve therapeutic concentrations
婴儿和幼儿肠内制剂泊沙康唑的给药剂量以达到治疗浓度
Jeffrey Harrington and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2051–2053,
36
Antimony used as rescue therapy in a kidney transplant recipient unresponsive to liposomal amphotericin B for chronic visceral leishmaniasis
两性霉素B脂质体治疗慢性内脏利什曼病无效的肾移植受者中使用锑剂作为挽救疗法
Natacha Mrozek and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2053–2056,
37
Is cefazolin an option for treatment of staphylococcal endogenous endophthalmitis?
头孢唑林是否可用于治疗葡萄球菌性内源性眼内炎？
Alexandra Morin and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2057–2058,
LETTER TO THE EDITOR（致编辑的信）
38
Use of teicoplanin monotherapy for the treatment of enterococcal infective endocarditis: a retrospective and comparative study at a referral centre—a counterpoint
单用替考拉宁治疗肠球菌感染性心内膜炎：一家转诊中心的回顾性和比较研究——反驳观点
Miguel Villamarín and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2059–2060,
Journal of Antimicrobial Chemotherapy Volume 80, Issue 8
抗菌化疗杂志 80卷 8期
https://academic.oup.com/jac/issue
Review(综述)
1
World Health Organisation’s Bacterial Pathogen Priority List (BPPL) 2017 and BPPL 2024 to combat global antimicrobial resistance crisis: ‘challenges and opportunities’
世界卫生组织2017年和2024年用以应对全球抗菌药物耐药性危机的细菌病原体优先名单（BPPL）：“挑战与机遇”
Vazhayil Hari Krishnaprasad and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2061–2069
Original Research(论著)
2
Aztreonam/avibactam activity against Enterobacterales from European medical centres: summary of 5years of surveillance prior to approval for clinical use (2019–2023)
氨曲南/阿维巴坦对欧洲医疗中心肠杆菌科细菌的活性：临床批准前5年（2019-2023年）监测总结
Helio S Sader and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2070–2079
3
High feasibility of salivary therapeutic drug monitoring in linezolid, but lower feasibility in tedizolid: a single-dose study in healthy subjects and a monocentric prospective exploratory study in patients who received linezolid
利奈唑胺唾液治疗药物监测可行性高，但替地唑胺可行性较低：一项健康受试者单剂量研究和一项接受利奈唑胺患者单中心前瞻性探索性研究
Hitoshi Kawasuji and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2080–2091
4
Establishment and validation of downsized hollow-fibre infection model and pharmacokinetics/pharmacodynamics analysis of VAN on Enterococcus faecium
缩小版中空纤维感染模型的建立与验证及万古霉素对粪肠球菌的药代动力学/药效学分析
Yukitaka Hayashi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2092–2099
5
Four-month clofazimine regimen for susceptible pulmonary TB: a randomized clinical trial
为期4个月的氯法齐明方案治疗敏感型肺结核：一项随机临床试验
Nusrat Shafiq and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2100–2108
6
An ex vivo model to determine transmembrane clearance of antimicrobials during continuous renal replacement therapy
用于确定连续性肾脏替代治疗期间抗菌药物跨膜清除率的体外模型
Cole McGrath and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2109–2116
7
Optimization and improvement of the disc diffusion method for mucoid Pseudomonas aeruginosa
黏液型铜绿假单胞菌纸片扩散法的优化与改进
Aixin Wang and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2117–2125
8
HIV-1 drug resistance among people living with HIV receiving dolutegravir-based anti-retroviral regimens in Uganda: a national laboratory-based survey using remnant viral load samples, 2022
乌干达接受基于多替拉韦抗逆转录病毒方案的HIV感染者中HIV-1耐药性情况：2022年一项基于国家实验室使用剩余病毒载量样本的调查
Christine Watera and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2126–2134
9
Population pharmacokinetics of weight-based compared with fixed dosing of CAP256V2LS, a broadly neutralizing antibody for HIV prevention in women
与固定剂量相比，基于体重给药的CAP256V2LS（一种用于女性HIV预防的广谱中和抗体）群体药代动力学研究
Sharana Mahomed and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2135–2144
10
Gut microbiota and weight gain in people with HIV on integrase inhibitors: a five-year longitudinal study
接受整合酶抑制剂治疗的HIV感染者肠道微生物群与体重增加情况：一项为期五年的纵向研究
Javier García-Abellán and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2145–2157
11
Development of a ribavirin dosing regimen in transplant recipients with chronic hepatitis E virus infection: a population pharmacokinetic and -dynamic model
慢性戊型肝炎病毒感染移植受者利巴韦林给药方案的开发：一项群体药代动力学和药效学模型研究
Midas B Mulder and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2158–2168
12
Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort
长效卡博特韦/利匹韦林在病毒受抑制的HIV感染者中的治疗中断有效性和预测因素：来自Icona队列的现实数据
Roberta Gagliardini and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2169–2178
13
Five-days-on-two-days-off (FOTO) versus daily bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV: a pilot randomized clinical trial
病毒受抑制的HIV感染者中，5天用药2天停药（FOTO）方案与每日比克替拉韦/恩曲他滨/丙酚替诺福韦方案的对比：一项初步随机临床试验
Hsin-Yun Sun and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2179–2186
14
Reliability of disc diffusion testing and molecular epidemiology of penicillin-susceptible Staphylococcus aureus bacteraemia
青霉素敏感金黄色葡萄球菌菌血症的纸片扩散试验可靠性和分子流行病学研究
Pernilla Kihlberg and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2187–2193
15
Outcomes of ceftriaxone 2g versus 1g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study
住院肺炎患者每日头孢曲松2克与1克疗效对比：一项全国性回顾性队列研究
Jumpei Taniguchi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2194–2202
16
Oleanolic acid derivative bardoxolone combats multidrug-resistant Staphylococcus aureus by destroying cell membrane and pyruvate metabolism pathway
齐墩果酸衍生物巴多昔隆通过破坏细胞膜和丙酮酸代谢途径对抗多重耐药金黄色葡萄球菌
Yun-Dan Zheng and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2203–2213
17
Evaluation of amoxicillin and benzylpenicillin therapy in early-onset neonatal sepsis: a pharmacometric external validation and simulation study
阿莫西林和苄青霉素治疗早期新生儿败血症的评估：一项药效计量学外部验证和模拟研究
Tom C Zwart and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2214–2225
18
48Week body composition changes in persons with HIV switching to dolutegravir plus lamivudine: a planned subanalysis of the DOLAM randomized clinical trial
HIV感染者换用多替拉韦加拉米夫定治疗48周身体成分变化：DOLAM随机临床试验的计划子分析
Elisa de Lazzari and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2226–2233
19
The impact of inter-infection time on antimicrobial resistance profiles in women with multiple urinary tract infections over time
多次尿路感染女性患者感染间隔时间对抗菌药物耐药性特征的影响
Trenton Honda and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2234–2240
20
Development and evaluation of a novel rapid immunochromatographic assay for the detection of DHA-producing Enterobacterales
一种检测产DHA肠杆菌科细菌的新型快速免疫层析法的开发与评估
Christian Moguet and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2241–2246
21
Enterococcus faecium bacteraemia: a multicentre observational study focused on risk factors for clinical and microbiological outcomes
粪肠球菌菌血症：一项关注临床和微生物学结局风险因素的多中心观察性研究
Matteo Rinaldi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2247–2256
22
Indolocarbazoles as host-directed therapeutics against intracellular infections by methicillin-resistant Staphylococcus aureus
靛红咔唑类化合物作为宿主导向疗法对抗甲氧西林耐药金黄色葡萄球菌细胞内感染
Robin H G A van den Biggelaar and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2257–2268
23
Clinical validation of antimicrobial dosing regimens for continuous renal replacement therapy based on an ex vivo dosing algorithm
基于体外给药算法的连续性肾脏替代治疗抗菌药物给药方案的临床验证
Christina Koenig and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2269–2279
24
Novel integrative and conjugative elements carrying cfr(B) and cfr(C) linezolid resistance genes in Clostridioides difficile isolates from calves, Italy
意大利牛犊艰难梭菌分离株中携带cfr(B)和cfr(C)利奈唑胺耐药基因的新型整合性和接合性元件
Andrea Brenciani and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2280–2284
25
Characterization of Carbapenemase-producing Enterobacterales isolated from patients returning from Sub-Saharan Africa, France, 2015–2022
2015-2022年从撒哈拉以南非洲返回的法国患者中分离出的产碳青霉烯酶肠杆菌科细菌的特征
Corentin Poignon and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2285–2294
26
Penicillin-susceptible ST398 with strong biofilm-forming ability poses a significant threat to osteoarticular infections
具有强生物膜形成能力的青霉素敏感ST398型对骨关节感染构成重大威胁
Ye Jin and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2295–2304
27
Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB
贝达喹啉、德拉马尼和莫西沙星与不同剂量苏特唑利或德帕唑利联合用药治疗药物敏感型肺结核的心脏安全性
Simon E Koele and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2305–2313
28
Comparison of ceftolozane/tazobactam and meropenem in treating bloodstream infections caused by extended-spectrum β-lactamase-producing Enterobacterales: a single-centre, retrospective, real-world study
头孢托唑坦/他唑巴坦与美罗培南治疗产超广谱β-内酰胺酶肠杆菌科细菌所致血流感染的对比：一项单中心回顾性现实研究
Dimitrios Basoulis and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2314–2322
Research Letters(研究信件)
29
Dalbavancin as chronic suppressive therapy in a patient undergoing monthly apheresis: a case report with therapeutic drug monitoring
达巴万星作为每月进行血浆置换术患者的长期抑制治疗：一项带治疗药物监测的病例报告
Carlo Pallotto and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2323–2324
30
A novel methicillin-resistant Staphylococcus aureus lineage (ST4174) with an uncharacterized SCCmec variant identified in Korean pigs
韩国猪体内发现的一种带有未表征SCCmec变体的新型甲氧西林耐药金黄色葡萄球菌谱系（ST4174）
Hyeonwoo Cho and Kun Taek Park
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2325–2326
31
Time fixes everything, but not always: 10years of persistent PI mutations in the absence of pharmacological pressure—a case report
时间能治愈一切，但并非总是如此：无药物压力下持续10年的蛋白酶抑制剂突变——一例病例报告
Layla Pagnucco and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2327–2330
32
Carbapenem resistance in Escherichia marmotae: characterization of IncL plasmids carrying blaOXA-48
土拨鼠埃希菌的碳青霉烯耐药性：携带blaOXA-48的IncL质粒特征
Astrid Rasmussen and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2330–2331
Letters to the Editor(致编辑的信)
33
Comment on: Clinical outcomes and the impact of treatment modalities in children with carbapenem-resistant Enterobacteriaceae bloodstream infections: a retrospective cohort study from a tertiary university hospital
述评：产碳青霉烯酶肠杆菌科细菌血流感染患儿的临床预后和治疗方式的影响：一项来自三级大学医院的回顾性队列研究
Jianjun Li and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2332
34
Clinical outcomes and the impact of treatment modalities in children with carbapenem-resistant Enterobacteriaceae bloodstream infections: a retrospective cohort study from a Tertiary University Hospital—right to reply—author’s response
产碳青霉烯酶肠杆菌科细菌血流感染患儿的临床预后和治疗方式的影响：一项来自三级大学医院的回顾性队列研究——作者回复
Gulhadiye Avcu
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2332–2333
Corrections(更正)
35
Correction to: Sofosbuvir as post-exposure prophylaxis for yellow fever–associated viscerotropic disease (YEL-AVD)
更正：索非布韦作为黄热病相关内脏热带病（YEL-AVD）暴露后预防用药
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2334
36
Correction to: Pandemic human-associated extended-spectrum β-lactamase-producing Escherichia coli lineages of ST38, ST131 and ST141 identified in Viennese dogs
更正：维也纳犬体内发现与人相关的大流行性产超广谱β-内酰胺酶大肠杆菌ST38、ST131和ST141谱系
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2335
37
Correction to: GP or ChatGPT? Ability of large language models (LLMs) to support general practitioners when prescribing antibiotics
更正：全科医生还是ChatGPT？大型语言模型（LLM）在全科医生开具抗生素处方时的辅助能力
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2336
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2
抗菌化疗杂志 80卷 增刊2期
https://academic.oup.com/jac/issue
SUPPLEMENT (补充)
CANWARD 2007-23
加拿大抗感染耐药监测项目（CANWARD）2007-2023年数据/报告
Foreword(前言)
1
The CANWARD studies: Canadian Antimicrobial Resistance Alliance (CARA) Canadian Hospital Ward Antibiotic Resistance Surveillance collection
加拿大抗感染耐药监测项目研究：加拿大抗微生物耐药联盟（CARA）加拿大医院病房耐药性监测数据集
James C Hurley and Jean-Yves Madec
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Page ii1
Supplement Papers(补充论文)
2
Seventeen years of the CANWARD study (2007–23)
加拿大抗感染耐药监测项目研究17年（2007-2023年）
George G Zhanel and Heather J Adam
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii2–ii4
3
Gram-positive pathogens from Canadian hospitals: 17years of results from the CANWARD study (2007–23)
来自加拿大医院的革兰氏阳性病原体：加拿大抗感染耐药监测项目研究的17年结果（2007-2023）
George G Zhanel and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii5–ii14
4
Gram-negative pathogens from Canadian hospitals: 17 years of results from the CANWARD study (2007–23)
来自加拿大医院的革兰氏阴性病原体：加拿大抗感染耐药监测项目研究的17年结果（2007-2023）
George G Zhanel and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii15–ii26
5
Characterization of methicillin-resistant Staphylococcus aureus in Canadian hospitals: 17 years of the CANWARD study (2007–23)
加拿大医院耐甲氧西林金黄色葡萄球菌的特征：加拿大抗感染耐药监测项目研究的17年（2007-2023）
Anissa Brahami and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii27–ii34
6
Comparison of antimicrobial resistance and serotype patterns in Streptococcus pneumoniae from blood cultures and respiratory specimens in Canadian hospitals from the CANWARD study (2007–23)
加拿大抗感染耐药监测项目研究中加拿大医院血液培养和呼吸道标本中肺炎链球菌抗微生物药物耐药性和血清型的比较（2007-23）
Heather J Adam and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii35–ii44
7
Increasing rates of ESBL-producing Escherichia coli and Klebsiella pneumoniae in Canadian Hospitals: 17 years of the CANWARD study, 2007–23
加拿大医院中产生ESBL的大肠杆菌和肺炎克雷伯菌的比率增加：加拿大抗感染耐药监测项目研究17年，2007-2023
Philippe Lagacé-Wiens and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii45–ii53
8
Characterization of ertapenem-resistant Enterobacterales in Canadian hospitals: 17 years of the CANWARD study (2007–23)
加拿大医院耐厄他培宁肠杆菌的特征：17年的加拿大抗感染耐药监测项目研究（2007-23）
Laura F Mataseje and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii54–ii61
9
Characterization of carbapenem-resistant Pseudomonas aeruginosa in Canadian hospitals: 6years of the CANWARD study (2018–23)
加拿大医院耐碳青霉烯假单胞菌的特征：6年的加拿大抗感染耐药监测项目研究（2018-23）
Melissa McCracken and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii62–ii71
10
Distribution and antimicrobial susceptibility profile of pathogens recovered from the bloodstream of Canadian patients: results from the CANWARD study (2007–23)
加拿大患者血液中病原菌的分布和药敏特征：来自加拿大抗感染耐药监测项目研究（2007-23）的结果
Andrew Walkty and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii72–ii82
Journal of Antimicrobial Chemotherapy Volume 80, Issue 9抗菌化疗杂志 80卷 9期
https://academic.oup.com/jac/issue
VIEWPOINT（观点）
1
Classifying patients with invasive fungal disease: towards a unified case definition?
侵袭性真菌病患者分类：能否达成统一的病例定义？
Mehmet Ergün and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2337–2343,
SYSTEMATIC REVIEW（系统综述）
2
Efficacy and safety of earlier switching to an oral antibiotic therapy for the treatment of Gram-positive bloodstream infections: a systematic review and meta-analysis
早期转换为口服抗生素治疗革兰氏阳性菌血流感染的疗效和安全性：一项系统综述和荟萃分析
ZhaoYi Tan and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2344–2360,
ORIGINAL RESEARCH（论著）
3
Determination of epidemiological cut-off values for Narasin, Salinomycin, Lasalocid and Monensin in Enterococcus faecium
屎肠球菌中那拉霉素、盐霉素、拉沙洛西钠和莫能菌素流行病学临界值的测定
Maria Laura Ferrando and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2361–2368,
4
Persistence of CXCR4-tropic virus in people living with four-class drug-resistant HIV and its clinical impact in the modern antiretroviral era
四类耐药HIV感染者体内CXCR4嗜性病毒的持续存在及其在现代抗逆转录病毒治疗时代的临床影响
Rebecka Papaioannu Borjesson and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2369–2374,
5
Hypertension and blood pressure changes with dolutegravir or comparator antiretroviral therapy in randomized trials through 96 weeks
随机试验中96周内使用多替拉韦或对照抗逆转录病毒疗法对高血压和血压变化的影响
Parul Patel and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2375–2383,
6
Comparative analysis of lipid profile changes in treatment-naïve people living with HIV on INSTI-based single-tablet regimens, BIC/FTC/TAF and DTG/3TC: real-world evidence from South Korea
基于整合酶抑制剂的单片复方制剂BIC/FTC/TAF和DTG/3TC在韩国初治HIV感染者中血脂谱变化的比较分析：来自现实世界的证据
So Yun Lim and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2384–2390,
7
A novel multilocus sequence typing scheme for Morganella spp.: population structure and introduction of quantitative metric for standardization of MLST scheme
摩根氏菌属的一种新型多位点序列分型方案：群体结构及引入用于标准化多位点序列分型方案的定量度量标准
Aymeric Jacquemin and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2391–2398,
8
Genomic characterization of multidrug-resistant extended-spectrum β-lactamase-producing Vibrio cholerae O1 strains from 2022 cholera outbreak in Kenya
2022年肯尼亚霍乱疫情中产超广谱β-内酰胺酶的多重耐药霍乱弧菌O1株的基因组特征
Diana Imoli and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2399–2407,
9
Impact of empiric anti-VRE therapy on survival in vancomycin-resistant enterococcal bloodstream infection
经验性抗万古霉素耐药肠球菌治疗对万古霉素耐药肠球菌血流感染患者生存率的影响
Tao-Hung Ou and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2408–2416,
10
Safety of topical tobramycin powder during operative treatment of fractures
骨折手术中使用局部妥布霉素粉末的安全性
Gregory M Schrank and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2417–2420,
11
Trimethoprim/sulfamethoxazole and risk of haemophagocytic lymphohistiocytosis (HLH): a literature review and disproportionality analysis using individual case safety reports from FAERS
复方磺胺甲恶唑与噬血细胞性淋巴组织细胞增多症（HLH）的风险：基于FAERS数据库个案安全报告的文献综述和比例失衡分析
Rinko Lau and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2421–2427,
12
Highly drug-resistant Vibrio cholerae harbouring blaPER-7 isolated from travellers returning to England
从返回英国的旅行者中分离出携带blaPER-7基因的高度耐药霍乱弧菌
Satheesh Nair and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2428–2432,
13
Overcoming antimicrobial resistance in Helicobacter pylori: the roles of collateral sensitivity and biofilm dynamics
克服幽门螺杆菌的抗菌药物耐药性：附带敏感性和生物膜动态的作用
Siddharth Singh and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2433–2441,
14
Clinical and microbiological analysis of bloodstream infections by four cefiderocol-resistant and not previously exposed NDM-producing Klebsiella pneumoniae
四种未接触过但对头孢地尔耐药的产NDM肺炎克雷伯菌所致血流感染的临床和微生物学分析
Maria Mazzitelli and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2442–2446,
15
Synergistic effects of DHA27 combined with gentamicin against methicillin-resistant Staphylococcus aureus in vitro and in vivo
DHA27与庆大霉素联合对耐甲氧西林金黄色葡萄球菌的体内外协同作用
Xuemin Chen and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2447–2458,
16
A multicentre study for determination of epidemiological cut-off values for Candida auris with EUCAST broth microdilution reference methodology
采用EUCAST肉汤微量稀释参考方法进行耳念珠菌流行病学临界值的多中心测定研究
Joseph Meletiadis and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2459–2465,
17
Impact of vancomycin resistance on attributable mortality among Enterococcus faecium bloodstream infections: propensity score analysis of a large, multicentre retrospective study
万古霉素耐药对屎肠球菌血流感染归因死亡率的影响：一项大型多中心回顾性研究的倾向评分分析
M Del Monte and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2466–2473,
18
Dynamics of dual CMV and EBV co-reactivation and emergence of resistance in an HSCT recipient
异基因造血干细胞移植受者中CMV和EBV双重再激活的动态变化及耐药性的出现
Martyna Pociupany and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2474–2483,
19
Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy
意大利米兰多西环素暴露后预防（DoxyPEP）使用者中用于治疗细菌性性传播感染的抗菌药物使用情况
Angelo Roberto Raccagni and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2484–2486,
20
Comparing the mortality of patients with sepsis using empirical piperacillin/tazobactam and cefepime: analysis of the MIMIC-IV database
使用经验性哌拉西林/他唑巴坦和头孢吡肟的脓毒症患者死亡率比较：基于MIMIC-IV数据库的分析
Yongseop Lee and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2487–2495,
21
Transmitted drug resistance profiles among people living with HIV-1 in Henan province, China, 2024
2024年中国河南省HIV-1感染者传播耐药情况
Jinjin Liu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2496–2502,
22
Fluctuations in copy number of the class A carbapenemase gene blaFRI appear to confer high-level carbapenem resistance
A类碳青霉烯酶基因blaFRI拷贝数的波动似乎赋予了高水平碳青霉烯耐药性
Makiko Noda and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2503–2512,
23
In vitro activity of ceftobiprole plus ampicillin against Enterococcus faecalis causing infective endocarditis: phenotypic and genotypic characterization
头孢比罗联合氨苄西林对引起感染性心内膜炎的粪肠球菌的体外活性：表型和基因型特征
Clara Moretó-Castellsaguéand others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2513–2523,
24
Paradoxical interaction between dalbavancin and β-lactams against endocarditis-associated Enterococcus faecalis clinical isolates
达巴万星与β-内酰胺类药物对心内膜炎相关粪肠球菌临床分离株的矛盾相互作用
David Luque Paz and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2524–2529,
25
Comparative evaluation of broth microdilution and gradient diffusion methods in Burkholderia cepacia complex susceptibility testing: implications of transitioning to ECV-based interpretation
伯克霍尔德菌复合群药敏试验中肉汤微量稀释法和梯度扩散法的比较评估：向基于ECV解释转变的影响
Wenjie Cui and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2530–2540,
26
Strengthening antimicrobial resistance diagnostics in National Reference Laboratories across One Health in South and Southeast Asia: impact of external quality assessment and targeted follow-up
加强南亚和东南亚“同一健康”国家参考实验室的抗菌药物耐药性诊断能力：外部质量评估和针对性随访的影响
Freshwork Ayalew Abegaz and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2541–2549,
RESEARCH LETTERS（研究快信）
27
TDM-guided meropenem/vaborbactam-based therapy for successful treatment of intra-abdominal and bloodstream infection caused by KPC-producing ceftazidime/avibactam-resistant Klebsiella pneumoniae in a paediatric liver transplant recipient
治疗药物监测指导下的美罗培南/瓦博巴坦疗法成功治疗儿童肝移植受者中产KPC且对头孢他啶/阿维巴坦耐药的肺炎克雷伯菌引起的腹腔和血流感染
Giovanni Mulé and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2550–2552,
28
Novel tmexC7D2-toprJ5 gene cluster and transposon Tn7759 carrying blaVIM-2 and blaOXA-10 genes in a carbapenem-resistant Pseudomonas putida from urban sewage
城市污水中碳青霉烯耐药恶臭假单胞菌中携带blaVIM-2和blaOXA-10基因的新型tmexC7D2-toprJ5基因簇和转座子Tn7759
Xinyuan Qiu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2552–2555,
29
Characterization of multiresistance gene optrA in Bacillus subtillis from China
中国枯草芽孢杆菌中多重耐药基因optrA的特征分析
Yongliang Che and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2555–2557,
30
Genomic characterization of a multidrug-resistant Mammaliicoccus sciuri strain isolated from urine of a patient from China
从中国患者尿液中分离出的一株多重耐药马氏鼠球菌的基因组特征
Fuqiang Ye and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2558–2560,
LETTERS TO THE EDITOR（致编辑的信）
31
Comment on: Isavuconazole therapeutic drug monitoring and association with adverse events
关于“艾沙康唑治疗药物监测及其与不良反应的关联”的评论
Mi Zhou and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2561–2562,
32
Comment on: Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalised patients with pneumonia: a nationwide retrospective cohort study
关于“住院肺炎患者每日2克与1克头孢曲松疗效比较：一项全国性回顾性队列研究”的评论
Satoru Mitsuboshi
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Page 2563,
33
Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study—authors’ response
住院肺炎患者每日2克与1克头孢曲松疗效比较：一项全国性回顾性队列研究——作者回复
Jumpei Taniguchi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2563–2564,
Journal of Antimicrobial Chemotherapy Volume 80, Issue 10抗菌化疗杂志 80卷 10期
https://academic.oup.com/jac/issue
REVIEWS（综述）
1
Long-acting cabotegravir and rilpivirine for the treatment of people with HIV: current landscape and challenges ahead
长效卡博特韦和利匹韦林治疗HIV感染者的现状与未来挑战
Luis Buzón-Martín and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2565–2586,
2
Systematic reviews and the Journal of Antimicrobial Chemotherapy; past, present and future. A systematic reappraisal
系统综述与《抗菌化疗杂志》：过去、现在与未来——系统再评估
James C Hurley
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2587–2596,
SYSTEMATIC REVIEWS（系统综述）
3
Studying intrapulmonary pharmacokinetics for tuberculosis treatment: a systematic review of methodology
研究肺结核治疗的肺内药代动力学：方法学的系统综述
Isabella van der Feltz and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2597–2608,
4
Global prevalence of nitrofurantoin-resistant uropathogenic Escherichia coli (UPEC) in humans: a systematic review and meta-analysis
全球人类中耐呋喃妥因的尿路致病性大肠埃希菌（UPEC）流行率：系统综述与荟萃分析
Christopher Larkin and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2609–2621,
ORIGINAL RESEARCH（研究论著）
5
Is ampicillin plus cephalosporins a therapeutic option for Ampicillin-Susceptible Enterococcus faecium?
氨苄青霉素联合头孢菌素是否为氨苄青霉素敏感的粪肠球菌的治疗选择？
Paula Bierge and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2622–2629,
6
Therapeutic efficacy monitoring of pyronaridine–artesunate (Pyramax®) in treating uncomplicated Plasmodium falciparum malaria in Gia Lai province, Vietnam from 2022 to 2023
2022-2023年越南嘉莱省青蒿琥酯-吡咯尼抗（Pyramax®）用于无并发症恶性疟原虫疟疾的治疗效果监测
Nguyen Van Thanh and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2630–2634,
7
Effectiveness of piperacillin/tazobactam loading dose for extended infusion dosing among patients with Gram-negative bacteraemia
哌拉西林/他唑巴坦负荷剂量用于革兰氏阴性菌血症患者延长输注给药的有效性
Savan Patel and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2635–2643,
8
Intrapulmonary concentrations of ceftobiprole high doses administered by continuous infusion in critically ill patients with community-acquired pneumonia
连续输注大剂量头孢比罗在社区获得性肺炎危重患者中的肺内浓度
Claire Roger and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2644–2653,
9
Cefixime versus benzathine penicillin G for the treatment of early syphilis—a randomized, controlled open label trial
头孢克肟与苄星青霉素G治疗早期梅毒的随机对照开放标签试验
Tamara Klementová and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2654–2658,
10
Trends in antifungal use among hospitalized patients in the USA, 2018–23
2018-2023年美国住院患者抗真菌药物使用趋势
Dallas J Smith and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2659–2664,
11
Clinical impact of the BCID2 and rapid AST VITEK® REVEALTM on antibiotic optimisation in critically ill patients with Gram-negative bloodstream infections: a quasi-experimental pre/post interventional study
BCID2和快速AST VITEK® REVEALTM对革兰氏阴性菌血流感染危重患者抗生素优化的临床影响：一项准实验性前后干预研究
Louis Oudiane and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2665–2675,
12
In vitro activity of thiamphenicol against drug-susceptible and drug-resistant strains of Mycoplasma genitalium
甲砜霉素对药物敏感和耐药生殖支原体菌株的体外活性
Sofie Skovmand and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2676–2681,
13
A priori optimization of levofloxacin dose regimen based on a population pharmacokinetics model
基于群体药代动力学模型的左氧氟沙星剂量方案先验优化
Emmanuel Enard and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2682–2692,
14
Model-informed individualized administration of ceftazidime–avibactam in critically ill patients: population pharmacokinetics studies and a parametric time-to-event analysis
危重患者头孢他啶-阿维巴坦的模型知情个体化给药：群体药代动力学研究和参数时间事件分析
Tingting Wu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2693–2704,
15
Development of blood culture time-to-positivity as a pharmacodynamic indicator for monitoring antibiotic therapy against MDR Gram-negative bacteria
开发血培养阳性时间作为监测针对多重耐药革兰氏阴性菌抗生素治疗的药效动力学指标
Irene Zaghi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2705–2713,
16
In vivo activity of ceftibuten-ledaborbactam oral combination against serine-β-lactamase-producing Enterobacterales: an assessment in the pyelonephritis and cystitis murine model
头孢布坦-莱达博巴坦口服联合用药对产丝氨酸-β-内酰胺酶肠杆菌科细菌的体内活性评估：在肾盂肾炎和膀胱炎小鼠模型中的评估
Christina Koenig and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2714–2718,
17
Faecal pharmacokinetics, microbiome, and bile acid changes in healthy subjects given intravenous followed by oral omadacycline; a Phase 1 clinical trial
健康受试者静脉注射后口服奥马环素的粪便药代动力学、微生物组和胆汁酸变化：一项1期临床试验
Jinhee Jo and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2719–2726,
18
Interlaboratory comparison of a dried blood spot assay for antiretroviral adherence: implications for clinical application
抗逆转录病毒治疗依从性干血斑检测法的实验室间比对：对临床应用的启示
Nathan Engel and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2727–2731,
19
A multicentre real-life prospective cohort study on effectiveness, durability and safety of long-acting injectable cabotegravir and rilpivirine in northern Italy: the LONGITUDE study
意大利北部长效注射用卡博特韦和利匹韦林有效性、持久性和安全性的现实中多中心前瞻性队列研究：LONGITUDE研究
Maria Mazzitelli and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2732–2741,
20
Assessment of the risk of developing cefepime-induced abnormal liver enzyme levels using the albumin–bilirubin score and fibrosis-4 index: a single-centre retrospective case–control study
使用白蛋白-胆红素评分和纤维化-4指数评估头孢吡肟诱导的肝酶水平异常发生风险：一项单中心回顾性病例对照研究
Hiroki Katsu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2742–2751,
21
Clinical course of patients with bloodstream infections enrolled in the BALANCE clinical trial
BALANCE临床试验中血流感染患者的临床病程
Sean W X Ong and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2752–2758,
22
Comparative outcomes of polymyxins in neurocritical care patients with carbapenem-resistant Gram-negative bacterial pneumonia: a retrospective cohort study
神经重症患者中多黏菌素治疗碳青霉烯类耐药革兰氏阴性菌肺炎的结果比较：一项回顾性队列研究
Qian Zeng and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2759–2772,
23
Distinct population structure and genomic context of NarAB between broiler and human clinical Enterococcus isolates
肉鸡和人类临床分离的粪肠球菌中NarAB的不同群体结构和基因组背景
Jayanth Balakuntla and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2773–2781,
24
Population pharmacokinetics of bictegravir in real-world people with HIV
现实中HIV感染者比克替拉韦的群体药代动力学
Pierre Ekobena and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2782–2789,
25
Rifampicin concentrations throughout the entire treatment duration of active tuberculosis; impact of sex and body mass index
活动性肺结核整个治疗期间利福平浓度：性别和体重指数的影响
Teres Samuelsson and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2790–2798,
26
Performance of disc diffusion and gradient strip test on different Mueller–Hinton agar media plates and ComASP® and Bruker UMIC® Cefiderocol Microdilution Panels for cefiderocol susceptibility testing in carbapenem-resistant Pseudomonas aeruginosa
在碳青霉烯类耐药铜绿假单胞菌中对头孢地尔敏感性测试使用不同穆勒-欣顿琼脂培养基平板和ComASP®及Bruker UMIC®头孢地尔微量稀释板的纸片扩散法和梯度条带测试的性能
Stefano Mancini and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2799–2806,
27
Placental transfer of medications to treat COVID-19, molnupiravir, favipiravir and nirmatrelvir/ritonavir, in the ex vivo human cotyledon model
在离体人类绒毛叶模型中治疗COVID-19的药物莫努匹拉韦、法维拉韦和奈玛特韦/利托那韦的胎盘转移
Solene Labaye and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2807–2813,
28
Synergistic cefiderocol-containing antibiotic combinations active against highly drug-resistant Acinetobacter baumannii patient isolates with diverse resistance mechanisms
针对具有多种耐药机制的高度耐药鲍曼不动杆菌患者分离株的含头孢地尔抗生素联合用药的协同作用
Justin Halim and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2814–2824,
29
Uptake of drug-reduced antiretroviral strategies and impact on costs over 2015–22: experience from an HIV clinic in Paris, France
2015-2022年药物减量抗逆转录病毒策略的采用情况及对成本的影响：来自法国巴黎一家HIV诊所的经验
L Sagaon-Teyssier and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2825–2833,
30
Molecular characterization of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae susceptible to delafloxacin
对达拉氟沙星敏感的侵袭性临床肺炎链球菌分离株中氟喹诺酮耐药性的分子特征
Emilia Cercenado and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2834–2843,
31
Genomic structure of class 1 and 2 integrons in non-typhoidal Salmonella isolated from food animals and related meat products in the USA
美国食品动物及其相关肉类产品中分离的非伤寒沙门氏菌1类和2类整合子的基因组结构
Chih-Hao Hsu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2844–2853,
32
Characterization of blaOXA-542-mediated carbapenem resistance in Acinetobacter baumannii
鲍曼不动杆菌中blaOXA-542介导的碳青霉烯类耐药性的特征
Jingchen Hao and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2854–2861,
33
Phenotypic and genotypic profiles of clinical isolates of various Nocardia species to carbapenems and fluoroquinolones
各种诺卡氏菌属临床分离株对碳青霉烯类和氟喹诺酮类的表型和基因型特征
Jing Yang and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2862–2872,
RESEARCH LETTERS（研究快报）
34
Oritavancin in a patient with recurrent endocarditis by Enterococcus faecalis: a new therapeutic option?
奥利他万星治疗粪肠球菌复发性心内膜炎患者：一种新的治疗选择？
Giulia Turicchi and Marco Bongiovanni
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2873–2874,
35
The catA1 chloramphenicol resistance gene originated in Atlantibacter hermannii
catA1氯霉素耐药基因起源于大西洋菌属赫尔曼尼菌
Robert A Moran and Ruth M Hall
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2874–2876,
36
Horizontal transmission of a multidrug-resistant IncM1 plasmid harbouring blaOXA-48 and blaCTX-M-14b among patient microbiotas
携带blaOXA-48和blaCTX-M-14b的多重耐药IncM1质粒在患者微生物群中的水平传播
Roberto Sierra and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2876–2879,
37
Antimicrobial activity of temocillin on ceftriaxone-resistant and ceftriaxone-susceptible isolates of Neisseria gonorrhoeae
替莫西林对头孢曲松耐药和头孢曲松敏感淋病奈瑟菌分离株的抗菌活性
Julie Brousseau and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2879–2881,
LETTERS TO THE EDITOR（致编辑的信）
38
Comment on: Bactericidal activity of antibiotic combinations against clinical isolates of Enterococcus gallinarum and Enterococcus casseliflavus
述评：抗生素联合用药对临床分离的鸡肠球菌和粪肠球菌的杀菌活性
Karl Oldberg and Magnus Rasmussen
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2882–2883,
39
Comment on: Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study
述评：住院肺炎患者每日2克与1克头孢曲松的疗效：一项全国性回顾性队列研究
Giancarlo Ceccarelli and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2884–2885,
40
Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study—right to reply—authors’ response
住院肺炎患者每日2克与1克头孢曲松的疗效：一项全国性回顾性队列研究——作者回应权——作者回复
Jumpei Taniguchi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2885–2886,
Journal of Antimicrobial Chemotherapy Volume 80, Issue Supplement_4抗菌化疗杂志 80卷 增刊4期
https://academic.oup.com/jac/issue/80/Supplement_4
SUPPLEMENT（补充）
Two Decades of BSAC Resistance Surveillance
英国抗菌化疗学会二十年耐药性监测
FOREWORD（前言）
1
Two Decades of BSAC Resistance Surveillance
英国抗菌化疗学会二十年耐药性监测
James C Hurley and Alan P Johnson
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Page iv1,
SUPPLEMENT PAPERS（补充论文）
2
Two decades of resistance surveillance by the British Society for Antimicrobial Chemotherapy: design, development, delivery, deficiencies and future directions
英国抗菌化疗学会二十年耐药性监测：设计、发展、实施、不足与未来方向
Alasdair P MacGowan and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv2–iv6,
3
The British Society for Antimicrobial Chemotherapy Resistance Surveillance Project: methods and limitations
英国抗菌化疗学会耐药性监测项目：方法与局限性
Michael Allen and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv7–iv21,
4
Antimicrobial resistance among Gram-positive agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019
英国和爱尔兰地区革兰氏阳性菌血流感染病原体的抗菌药物耐药性趋势（2001 - 2019年）
Rosy Reynolds and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv22–iv35,
5
Antimicrobial resistance among Gram-negative agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019
英国和爱尔兰地区革兰氏阴性菌血流感染病原体的抗菌药物耐药性趋势（2001 - 2019年）
Rosy Reynolds and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv36–iv48,
6
Antimicrobial resistance among agents of hospital-acquired lower respiratory tract infection in the UK and Ireland: trends from 2008/2009 to 2018/2019
英国和爱尔兰地区医院获得性下呼吸道感染病原体的抗菌药物耐药性趋势（2008/2009 - 2018/2019年）
Rosy Reynolds and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv49–iv59,
7
Antimicrobial resistance among agents of community-associated lower respiratory tract infection in the UK and Ireland: trends from 1999/2000 to 2018/2019
英国和爱尔兰地区社区获得性下呼吸道感染病原体的抗菌药物耐药性趋势（1999/2000 - 2018/2019年）
Rosy Reynolds and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv60–iv71,
8
Trends of serotypes and resistance among Streptococcus pneumoniae in the UK and Ireland (1999–2019)
英国和爱尔兰地区肺炎链球菌血清型及耐药性趋势（1999 - 2019年）
Carolyne Horner and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv72–iv86,
9
Applications and benefits of the British Society for Antimicrobial Chemotherapy Resistance Surveillance Project—legacy and future
英国抗菌化疗学会耐药性监测项目的应用与益处——成果与未来
Benjamin J Parcell and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv87–iv95,
Journal of Antimicrobial Chemotherapy Volume 80, Issue 11抗菌化疗杂志 80卷 11期
https://academic.oup.com/jac/issue
VIEWPOINTS（观点）
1
Modification of antimicrobial susceptibility testing methods
抗菌药物敏感性检测方法的修改
Ian Morrissey and Jean B Patel
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2887–2888,
2
Viewpoint: global antimicrobial stewardship accreditation is needed: the experience in Kentucky, USA
观点：需要建立全球抗菌药物管理认证体系：美国肯塔基州的经验
Ashley M Wilde and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2889–2891,
REVIEWS（综述）
3
Phages connect the biological dots of antimicrobial resistance: from genesis and spread to alternative treatment modules
噬菌体揭示抗菌药物耐药性的生物学脉络：从起源与传播到替代治疗模式
Cleo Anastassopoulou and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2892–2901,
4
Molecular drivers of fusion plasmid: mechanistic insights and evolutionary implications
融合质粒的分子驱动因素：机制见解与进化意义
Ziyi Liu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2902–2911,
ORIGINAL RESEARCH（研究论著）
5
Emergence of livestock-associated MRSA clonal complex 398 in Thailand’s swine industry
泰国养猪业中出现与牲畜相关的MRSA克隆复合体398
Pawarut Narongpun and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2912–2917,
6
Peripheral neuropathy during long-term suppressive therapy with tedizolid: a case series
长期使用替达拉韦抑制治疗期间出现周围神经病变：系列病例报告
Tomaso Beringheli and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2918–2922,
7
Low bacterial metabolism as a central mechanism of antimicrobial resistance and potential therapeutic target of staphylococcal biofilms in ventricular assist device driveline infections
细菌低代谢作为抗菌药物耐药性的核心机制及心室辅助装置驱动线感染中葡萄球菌生物膜的潜在治疗靶点
Yao Sun and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2923–2933,
8
The pivotal role of acnA in linking carbon metabolism to virulence and antimicrobial resistance in methicillin-resistant Staphylococcus aureus
acnA在连接碳代谢与耐甲氧西林金黄色葡萄球菌的毒力和抗菌药物耐药性中的关键作用
Jiahui Li and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2934–2944,
9
Pharmacokinetics of rifampicin and isoniazid in patients with HIV–tuberculosis coinfection receiving efavirenz-based antiretroviral treatment: an ANRS12292–RIFAVIRENZ sub-study
接受以依非韦伦为基础的抗逆转录病毒治疗的HIV-结核病共感染患者中利福平和异烟肼的药代动力学：ANRS12292-RIFAVIRENZ子研究
Thibaut Gelé and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2945–2953,
10
Novel mutations associated with clofazimine resistance in Mycobacterium intracellulare
胞内分枝杆菌中与氯法齐明耐药相关的新型突变
Xiuzhi Jiang and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2954–2957,
11
Physiologically informed in vitro framework reveals context-dependent combinatory activity of niclosamide–colistin against Gram-negative bacteria
基于生理信息的体外框架揭示了针对革兰氏阴性菌的硝基咪唑-多粘菌素组合的情境依赖性活性
Mariana Romero-Gonzalez and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2958–2969,
12
In vitro evolution provides insights into mechanisms of Mycoplasma genitalium resistance to moxifloxacin
体外进化揭示生殖支原体对莫西沙星的耐药机制
Teck-Phui Chua and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2970–2977,
13
The toxin–antitoxin system SavRS contributes to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus by mediating cell wall thickening
毒素-抗毒素系统SavRS通过介导细胞壁增厚促进万古霉素中间型金黄色葡萄球菌对万古霉素的耐药性
Weifeng Xu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2978–2988,
14
Molecular insights into carbapenemase-producing Enterobacterales from Senegal
塞内加尔产碳青霉烯酶肠杆菌目细菌的分子特征
Ousmane Sow and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2989–3000,
15
Population pharmacokinetic model of linezolid and its metabolite PNU-142300 in elderly patients
老年患者中利奈唑胺及其代谢产物PNU-142300的群体药代动力学模型
Xianglong Chen and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3001–3010,
16
In vitro activity of contezolid and other comparators against clinical Staphylococcus and Enterococcus: a multicenter study in China
在中国开展的一项多中心研究中，康替唑胺及其他对照药物对临床分离的金黄色葡萄球菌和肠球菌的体外活性
Rongqi Lu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3011–3020,
17
Co-existence of the oxazolidinone resistance genes cfr and optrA on a novel multiresistance plasmid from a methicillin-resistant Macrococcoides bohemicum strain
从一株耐甲氧西林的马科考代菌属波希米亚菌株中发现的携带恶唑烷酮耐药基因cfr和optrA的新型多重耐药质粒
Yao Zhu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3021–3025,
18
Multidrug resistance and recurrence in urinary bacteraemia among cancer patients
癌症患者中尿路菌血症的多药耐药性和复发情况
Ignacio Grafia and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3026–3033,
19
Rapid replacement of blaKPC variant in ST11 carbapenem-resistant and hypervirulent Klebsiella pneumoniae contributed to ceftazidime/avibactam resistance during severe in vivo infection
在严重的体内感染期间，ST11型碳青霉烯耐药且高毒力的肺炎克雷伯菌中blaKPC变体的快速替代导致头孢他啶/阿维巴坦耐药
Ping Yang and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3034–3042,
20
Potential human health risk of carbapenem-non-susceptible Pseudomonas aeruginosa from companion animals
伴侣动物中碳青霉烯类不敏感铜绿假单胞菌对人类健康的潜在风险
Jirachaya Toyting-Hiraishi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3043–3056,
21
Assessment of an LC coupled with tandem MS (LC-MS/MS) tool in the detection of antimicrobial resistance mechanisms in Enterobacterales
液相色谱-串联质谱（LC-MS/MS）工具在检测肠杆菌目细菌抗菌药物耐药机制中的应用评估
Anna Witkowska and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3057–3064,
22
Multidrug efflux pumps and innate azole resistance of Mucor lusitanicus
毛霉属葡萄牙菌的多药外排泵及其固有唑类耐药性
Stephanie Toepfer and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3065–3078,
23
Ivermectin dosing for children under 2 years
2岁以下儿童的伊维菌素剂量
Wenyu Yang and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3079–3081,
24
Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort
一线拉米夫定/多替拉韦抗逆转录病毒疗法在HIV感染者中的有效性：来自ICONA基金会队列的现实数据
Alessandra Vergori and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3082–3091,
25
Eligibility and factors associated with long-acting injectable cabotegravir-rilpivirine initiation in an urban academic HIV clinic
城市学术型HIV诊所中长效注射用卡博特韦-利匹韦林启动的资格及关联因素
Geoffroy Liegeon and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3092–3100,
26
Evaluation of HIV-1 DNA resistance evolution in highly treatment-experienced and multi-resistant individuals under suppressive antiretroviral therapy: a longitudinal study from the PRESTIGIO Registry
在接受抑制性抗逆转录病毒治疗的高度治疗经验丰富和多药耐药个体中，HIV-1 DNA耐药演变的评估：来自PRESTIGIO登记处的纵向研究
D Armenia and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3101–3106,
27
Sequential antibiotic exposure restores antibiotic susceptibility
序贯抗生素暴露恢复抗生素敏感性
Farhan R Chowdhury and Brandon L Findlay
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3107–3117,
28
Dermatological adverse effects of doxycycline as post-exposure prophylaxis for sexually transmitted infections among men who have sex with men: real-world findings from a multicentre study
在男男性行为者中，使用多西环素作为性传播感染暴露后预防的皮肤科不良反应：一项多中心研究的现实发现
Ling-Ya Chen and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3118–3122,
29
Phenotype–genotype discordance in antimicrobial resistance profiles of Gram-negative uropathogens recovered from catheter-associated urinary tract infections in Egypt
埃及导管相关尿路感染中分离的革兰氏阴性尿路病原菌抗菌药物耐药性表型-基因型不一致性
Mohamed Eladawy and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3123–3132,
30
How should APOBEC3-induced resistance mutations be considered in the management of antiretroviral therapy?
在抗逆转录病毒治疗管理中，应如何考虑APOBEC3诱导的耐药突变？
Marie Gilbert and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3133–3138,
31
In vitro evaluation of olorofim and antifungal combinations against Aspergillus and Candida species
奥洛芬和抗真菌药物组合对曲霉菌和念珠菌属的体外评价
Corinne Pinder and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3139–3149,
32
Antagonistic interaction between posaconazole and olorofim in a murine model of invasive pulmonary aspergillosis
在侵袭性肺曲霉病小鼠模型中，泊沙康唑与奥洛芬之间的拮抗作用
Christopher A Darlow and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3150–3159,
33
High level of archived and circulating HIV-1 drug resistance mutations in adolescents with a detectable viremia in Cameroon
喀麦隆可检测到病毒载量的青少年中HIV-1药物耐药突变的存档和循环水平较高
Armando B D Djiyou and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3160–3164,
RESEARCH LETTERS（研究快讯）
34
SCY-247, a novel second-generation triterpenoid antifungal, demonstrates high in vitro activity against genetically diverse Candida auris isolates, including FKS1 mutants
新型第二代三萜类抗真菌药物SCY-247对包括FKS1突变体在内的多种基因型耳道假丝酵母菌显示出高体外活性
Bram Spruijtenburg and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3165–3166,
35
Drug–drug interactions between tirzepatide and antiretrovirals: time to reassess and reassure?
替西帕肽与抗逆转录病毒药物之间的药物-药物相互作用：是时候重新评估和安心了吗？
Andrea Poloni and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3167–3168,
36
Does the use of topical azoles have an impact on antifungal resistance?
局部使用唑类药物对抗真菌耐药性有影响吗？
Jean-Yves Maillard
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3168–3186,
37
Leakage of cabotegravir and rilpivirine in HIV patients receiving long-acting injectable antiretroviral therapy
接受长效注射用抗逆转录病毒治疗的HIV患者中卡博特韦和利匹韦林的泄漏情况
Samir Benkouiten and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3187–3188,
CORRECTION（更正）
38
Correction to: Clinical and microbiological analysis of bloodstream infections by four cefiderocol-resistant and not previously exposed NDM-producing Klebsiella pneumoniae
更正：对四种产NDM且之前未接触过头孢地洛的耐药肺炎克雷伯菌引起的血流感染的临床和微生物学分析
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Page 3189,
100 项与 盐酸莫西沙星 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 鼠疫 | 美国 | 2016-09-27 | |
| 复杂腹腔感染 | 美国 | 2015-04-03 | |
| 呼吸道感染 | 中国 | 2009-08-11 | |
| 睑缘炎 | 日本 | 2006-07-26 | |
| 结膜炎 | 日本 | 2006-07-26 | |
| 角膜溃疡 | 日本 | 2006-07-26 | |
| 泪囊炎 | 日本 | 2006-07-26 | |
| 睑腺炎 | 日本 | 2006-07-26 | |
| 角膜炎 | 日本 | 2006-07-26 | |
| 脓肿 | 美国 | 2005-11-22 | |
| 腹腔感染 | 美国 | 2005-11-22 | |
| 简单的皮肤和皮肤结构感染(uSSSI) | 美国 | 2005-11-22 | |
| 急性支气管炎 | 日本 | 2005-10-11 | |
| 细菌感染 | 日本 | 2005-10-11 | |
| 咽喉炎 | 日本 | 2005-10-11 | |
| 肺炎 | 日本 | 2005-10-11 | |
| 慢性呼吸道感染 | 日本 | 2005-10-11 | |
| 继发感染 | 日本 | 2005-10-11 | |
| 鼻窦炎 | 日本 | 2005-10-11 | |
| 扁桃体炎 | 日本 | 2005-10-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 耐多药结核病 | 临床3期 | 巴西 | 2018-07-30 | |
| 耐多药结核病 | 临床3期 | 格鲁吉亚 | 2018-07-30 | |
| 耐多药结核病 | 临床3期 | 马来西亚 | 2018-07-30 | |
| 耐多药结核病 | 临床3期 | 菲律宾 | 2018-07-30 | |
| 耐多药结核病 | 临床3期 | 俄罗斯 | 2018-07-30 | |
| 耐多药结核病 | 临床3期 | 南非 | 2018-07-30 | |
| 耐多药结核病 | 临床3期 | 坦桑尼亚 | 2018-07-30 | |
| 耐多药结核病 | 临床3期 | 乌干达 | 2018-07-30 | |
| 多重耐药性肺结核 | 临床3期 | 格鲁吉亚 | 2015-02-01 | |
| 多重耐药性肺结核 | 临床3期 | 肯尼亚 | 2015-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床1期 | 37 | (PRO-231) | 鹽蓋餘窪鏇鑰蓋膚築鹽 = 鑰醖膚繭憲鹹憲願網襯 鑰願餘衊憲積襯鏇鏇膚 (鑰製遞艱願顧淵顧願選, 淵構憲構遞衊壓鬱願繭 ~ 鏇齋遞願糧觸壓窪願範) 更多 | - | 2025-06-15 | ||
(VIGAMOXI®) | 鹽蓋餘窪鏇鑰蓋膚築鹽 = 膚範構壓簾鏇獵夢製繭 鑰願餘衊憲積襯鏇鏇膚 (鑰製遞艱願顧淵顧願選, 醖淵膚獵繭衊遞獵鹽範 ~ 膚壓襯齋鏇壓憲鬱鏇網) 更多 | ||||||
临床4期 | 87 | (Bromfenac Group) | 糧醖淵膚鏇網鹹簾積憲(簾襯觸窪壓鏇廠積選願) = 衊壓醖選觸糧齋顧憲襯 鬱積鹽範獵簾選襯遞鹹 (淵襯襯鹹願餘範膚窪糧, 15.4) 更多 | - | 2025-05-06 | ||
糧醖淵膚鏇網鹹簾積憲(簾襯觸窪壓鏇廠積選願) = 艱選夢顧膚鹽夢壓壓齋 鬱積鹽範獵簾選襯遞鹹 (淵襯襯鹹願餘範膚窪糧, 14.8) 更多 | |||||||
临床4期 | 108 | (Intraoperative Antibiotics (Abx) Only; no Postoperative Topical Antibiotics) | 鑰鏇蓋網簾製鹹壓襯網(顧廠鹹廠鬱醖夢選憲齋) = 艱範構遞鏇廠壓憲艱膚 淵窪窪憲鹹顧衊淵膚蓋 (鬱廠衊糧餘蓋淵鏇觸顧, 0) 更多 | - | 2025-03-28 | ||
(Intraoperative Antibiotics (Abx); Postoperative Topical Antibiotics Four Times a Day for 1 Week) | 鑰鏇蓋網簾製鹹壓襯網(顧廠鹹廠鬱醖夢選憲齋) = 製夢餘選網膚壓憲醖憲 淵窪窪憲鹹顧衊淵膚蓋 (鬱廠衊糧餘蓋淵鏇觸顧, 0) 更多 | ||||||
临床1期 | - | 64 | moxifloxacin placebo (Group 1) | 簾顧築壓願鑰鹽鑰襯憲(鏇鹹願選膚鑰鹹簾積鑰) = 壓願衊獵糧憲憲範鹹繭 願鹽餘醖製醖夢觸鏇繭 (憲鹽艱遞鏇醖齋餘構蓋, 15.198) 更多 | - | 2025-03-14 | |
Pritelivir placebo, moxifloxacin and moxifloxacin placebo (Group 2a) | 簾顧築壓願鑰鹽鑰襯憲(鏇鹹願選膚鑰鹹簾積鑰) = 糧襯齋積淵獵夢餘淵鏇 願鹽餘醖製醖夢觸鏇繭 (憲鹽艱遞鏇醖齋餘構蓋, 17.208) 更多 | ||||||
临床2期 | 26 | BPaMZ (BPaMZ) | 觸簾顧夢餘繭簾鏇餘鹹(觸製膚壓簾衊糧願壓鏇) = 繭鏇糧淵願壓鏇襯製艱 積蓋蓋製網齋窪製醖鬱 (夢膚獵餘觸夢範鑰鑰簾, 97.3) 更多 | - | 2024-09-19 | ||
(BPaMZ Baseline) | 獵醖廠選憲鹽蓋築衊鹹(築鹹糧艱艱壓範餘願繭) = 鏇餘積願網鬱艱廠窪積 窪觸齋餘網繭鏇鹽蓋壓 (襯夢觸顧憲膚艱餘鏇淵, 淵鹹鏇醖遞壓廠壓範夢 ~ 選築醖鹹廠艱壓鑰選廠) 更多 | ||||||
临床2期 | 455 | 廠艱襯簾鹽顧窪蓋鬱繭(積鬱廠蓋壓繭廠憲觸簾) = three participants [1%] 膚糧鏇積簾網艱醖遞繭 (醖淵簾繭窪醖艱觸築膚 ) 更多 | 积极 | 2024-09-01 | |||
临床2/3期 | 552 | rifampicin (Standard care) | 衊齋築遞範糧壓獵網襯(鏇廠築繭壓願糧廠簾餘) = 壓壓獵鏇醖蓋廠繭構顧 選窪淵簾夢製醖繭築餘 (鏇鏇壓遞憲製淵壓鹹選 ) 更多 | 积极 | 2024-02-01 | ||
(BPaLM) | 衊齋築遞範糧壓獵網襯(鏇廠築繭壓願糧廠簾餘) = 願醖齋製醖蓋蓋觸範遞 選窪淵簾夢製醖繭築餘 (鏇鏇壓遞憲製淵壓鹹選 ) 更多 | ||||||
临床2/3期 | 455 | ethambutol+rifampicin+isoniazid+pyrazinamide (Drug Sensitive-TB 2HRZE/4HR) | 廠鑰窪衊窪醖鏇鏇遞壓 = 網蓋鹹醖製鹹製艱壓壓 繭廠鹽獵鹽繭顧鹹積築 (蓋顧選製艱齋蓋糧糧鏇, 鹹淵膚顧艱遞顧構製範 ~ 繭淵齋鹽壓壓膚夢鏇繭) 更多 | - | 2023-11-08 | ||
4BPaMZ (Drug Sensitive-TB 4BPaMZ) | 廠鑰窪衊窪醖鏇鏇遞壓 = 廠憲衊顧鹹網衊鏇醖獵 繭廠鹽獵鹽繭顧鹹積築 (蓋顧選製艱齋蓋糧糧鏇, 醖繭觸齋蓋糧窪願襯簾 ~ 顧廠膚築顧鑰糧醖齋糧) 更多 | ||||||
N/A | 1,552 | (Antibiotics Therapy Arm) | 顧衊窪艱窪醖簾觸構積(構餘醖願積艱膚構遞蓋) = 選艱積構獵齋壓觸遞願 淵膚壓遞襯壓窪鹹壓觸 (願醖鏇壓壓醖願積遞醖, 0.13) 更多 | - | 2023-04-18 | ||
Appendectomy (Appendectomy Arm) | 顧衊窪艱窪醖簾觸構積(構餘醖願積艱膚構遞蓋) = 鹹選憲鹽窪觸鬱淵衊願 淵膚壓遞襯壓窪鹹壓觸 (願醖鏇壓壓醖願積遞醖, 0.13) 更多 | ||||||
临床2/3期 | 301 | 襯網憲網淵鏇糧築願鏇(網餘網夢窪範獵觸獵築) = 繭餘遞醖遞夢鏇壓構糧 網膚範淵製鏇夢範鹹選 (簾範觸廠膚夢膚膚餘鹽 ) | 积极 | 2022-12-22 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用